

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | DEC 18 | CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS | 4 | DEC 18 | CA/CAPplus patent kind codes updated |
| NEWS | 5 | DEC 18 | MARPAT to CA/CAPplus accession number crossover limit increased to 50,000 |
| NEWS | 6 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS | 7 | DEC 27 | CA/CAPplus enhanced with more pre-1907 records |
| NEWS | 8 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS | 9 | JAN 16 | CA/CAPplus Company Name Thesaurus enhanced and reloaded |
| NEWS | 10 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS | 11 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS | 12 | JAN 22 | CA/CAPplus updated with revised CAS roles |
| NEWS | 13 | JAN 22 | CA/CAPplus enhanced with patent applications from India |
| NEWS | 14 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS | 15 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS | 16 | FEB 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS | 17 | FEB 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS | 18 | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS | 19 | FEB 26 | MEDLINE reloaded with enhancements |
| NEWS | 20 | FEB 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS | 21 | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS | 22 | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS | 23 | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS | 24 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS | 25 | MAR 16 | CASREACT coverage extended |
| NEWS | 26 | MAR 20 | MARPAT now updated daily |
| NEWS | 27 | MAR 22 | LWPI reloaded |
| NEWS EXPRESS | | | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS IPC8 | | | For general information regarding STN implementation of IPC 8 |
| NEWS X25 | | | X.25 communication option no longer available |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 02:36:43 ON 30 MAR 2007

=> FIL REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 02:37:04 ON 30 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2007 HIGHEST RN 928615-67-2

DICTIONARY FILE UPDATES: 28 MAR 2007 HIGHEST RN 928615-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10997191.str



```

chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
14
chain bonds :
4-10 6-14 10-11 10-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
3-9 4-10 6-14 7-8 8-9 10-11 10-12
exact bonds :
2-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

G1:H,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> S L1 SAM

SAMPLE SEARCH INITIATED 02:37:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 72 TO ITERATE

100.0% PROCESSED 72 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

50 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 931 TO 1949
PROJECTED ANSWERS: 688 TO 1592

L2 50 SEA SSS SAM L1

=> S L1 FULL

FULL SEARCH INITIATED 02:37:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1327 TO ITERATE

100.0% PROCESSED 1327 ITERATIONS 1054 ANSWERS
SEARCH TIME: 00.00.01

L3 1054 SEA SSS FUL L1

=> FILE CAPLUS

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 172.10 | 172.31 |

FILE 'CAPLUS' ENTERED AT 02:37:34 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 28 Mar 2007 (20070328/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3

L4 9 L3

=> S L3 FULL

L5 9 L3

=> d l4 ibib hitstr abs 1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1252488 CAPLUS
DOCUMENT NUMBER: 146:27853
TITLE: Preparation of pyrazolo[4,3-d]pyrimidine derivatives as CRF receptor antagonists
INVENTOR(S): Kashiwagi, Toshihiko; Takamuro, Iwao; Watanabe, Yumi; Yato, Michihisa
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2006126718 | A1 | 20061130 | WO 2006-JP310828 | 20060524 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: JP 2005-155310 A 20050527

OTHER SOURCE(S): MARPAT 146:27853


IT 916064-96-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[4,3-d]pyrimidine derivs. as CRF receptor antagonists)

RN 916064-96-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-chloro-4-(trifluoromethyl)phenyl]-N5-ethyl-N7-methyl-N7-2-pyridinyl- (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aromatic ring, (un)substituted alkyl, (un)substituted amino; R2 = (un)substituted aromatic ring; R3 = (un)substituted alkyl; R4 = H, alkyl, halo, etc.] and their pharmacol. acceptable salts were prepared For example, reaction of compound II, e.g., prepared from 4-nitro-1H-pyrazole-3-carboxylic acid in 8 steps, with

iodoethane followed by treatment with trifluoroacetic acid afforded compound III. Of note, compds. I are useful as CRF (corticotropin releasing factor) receptor antagonists for the treatment of depression, anxiety, etc. (no data).

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1202023 CAPLUS

DOCUMENT NUMBER: 145:505469

TITLE: Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide as PDE-5 inhibitors

INVENTOR(S): Entwistle, David Andrew; Marshall, Peter Wallance; Taylor, Stefan Colin John

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 72pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2006120552 | A2 | 20061116 | WO 2006-IB1233 | 20060503 |
| WO 2006120552 | A3 | 20070118 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| JP 2006316058 | A | 20061124 | JP 2006-132110 | 20060511 |
| PRIORITY APPLN. INFO.: | | | US 2005-680445P | P 20050512 |
| | | | US 2005-681711P | P 20050517 |


IT 853003-48-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and anhydrous crystalline forms of N-[ethoxyethyl(N-ethyl-N-methylamino)(methylpyridinylamino)pyrazolo[4,3-d]pyrimidinecarbonyl]methanesulfonamide as PDE-5 inhibitors)

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 853004-52-1P 853006-51-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and anhydrous crystalline forms of N-[ethoxyethyl(N-ethyl-N-methylamino)(methylpyridinylamino)pyrazolo[4,3-d]pyrimidinecarbonyl]methanesulfonamide as PDE-5 inhibitors)

RN 853004-52-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-51-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



I

AB The invention comprises anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide (I), pharmaceutical comps. comprising at least one such form, methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and methods for preparing such forms. Example compound I was prepared by N-alkylation of di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate with 2-ethoxyethyl bromide; the resulting di-Me 1-(2-ethoxyethyl)-4-nitro-1H-pyrazole-3,5-dicarboxylate, which underwent hydrolysis to give the pyrazole-5-carboxylic acid derivative, which underwent amidation to give the corresponding amide, which underwent reduction to give Me 4-amino-5-carbamoyl-1-(2-ethoxyethyl)-1H-pyrazole-3-carboxylate, which underwent cyclization with N,N'-carbonyldiimidazole to give Me 1-(2-ethoxyethyl)-5,7-dioxo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which which underwent chlorination to give Me 5,7-dichloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which underwent substitution with 2-amino-4-methylpyridine; the resulting Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate underwent hydrolysis to give the corresponding carboxylic acid, which underwent amidation to give the methanesulfonamide derivative, which underwent substitution with N-methylethylamine to give compound I. Various methods to obtained different crystalline forms of I is also discussed. Compound I was evaluated for its PDE-5 inhibitory activity.

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:412090 CAPLUS

DOCUMENT NUMBER: 144:450729

TITLE: Preparation of novel 5,7-diaminopyrazolo[4,3-d]pyrimidines as PDE5 inhibitors for treating hypertension

INVENTOR(S): Acker, Brad Alan; Hughes, Robert Owen; Jacobsen, Eric John; Lu, Hwang-Fun; Rogers, Thomas Edward; Tollefson, Michael Brent; Walker, John Keith

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA

SOURCE: PCT Int. Appl., 244 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2006046135 | A2 | 20060504 | WO 2005-IB3326 | 20051017 |
| WO 2006046135 | A3 | 20060817 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.: US 2004-622941P P 20041028

OTHER SOURCE(S): MARPAT 144:450729

IT 885472-08-2P 885472-30-0P, tert-Butyl 4-[7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperazine-1-carboxylate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (PDE5 inhibitor; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)


RN 885472-08-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-(ethoxymethyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-07-1

CMF C25 H34 F3 N9 O4




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 885472-30-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792969-22-3P 792969-47-2P 792970-86-6P
 794511-60-7P 794511-61-8P 794511-62-9P,
 1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-(piperazin-1-yl)-N-(pyrimidin-4-yl)-
 1H-pyrazolo[4,3-d]pyrimidin-7-amine 885469-95-4P,
 [1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]-1H-
 pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885469-96-5P
 885469-97-6P 885469-98-7P, 1-[1-(2-Ethoxyethyl)-3-ethyl-
 7-[(4-fluorophenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-
 carboxamide 885469-99-8P 885470-00-8P
 885470-01-9P 885470-02-0P 885470-03-1P,

1-[3-Ethyl-7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide
885470-04-2P 885470-05-3P 885470-06-4P
885470-08-6P 885470-09-7P 885470-10-0P
885470-11-1P 885470-12-2P 885470-13-3P
885470-14-4P 885470-15-5P 885470-16-6P
885470-17-7P 885470-18-8P 885470-19-9P
885470-20-2P 885470-21-3P 885470-22-4P
885470-24-6P 885470-25-7P 885470-26-8P,
3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(pyrazin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885470-27-9P 885470-28-0P, 1-[3-Ethyl-7-[(pyrazin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide 885470-29-1P, [1-[3-Ethyl-7-[(pyrazin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885470-30-4P,
3-Ethyl-5-(piperazin-1-yl)-N-(pyrazin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-31-5P, 3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(4-methylpyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-32-6P 885470-33-7P,
1-[3-Ethyl-7-[(4-methylpyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide 885470-34-8P, [1-[3-Ethyl-7-[(4-methylpyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885470-35-9P, 3-Ethyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-36-0P
885470-37-1P 885470-38-2P, 1-[3-Ethyl-7-[(6-methylpyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide
885470-39-3P, [1-[3-Ethyl-7-[(6-methylpyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885470-40-6P, 3-Ethyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-41-7P, 3-Ethyl-N-(4-fluorophenyl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-42-8P 885470-43-9P,
1-[3-Ethyl-7-[(pyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide
885470-44-0P, [1-[3-Ethyl-7-[(pyridin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885470-45-1P, 3-Ethyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-46-2P, 3-Ethyl-N'-(4-fluorophenyl)-N-methyl-N-(1-methylpiperidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-47-3P 885470-48-4P,
1-[3-Ethyl-7-[(4-methylpyrimidin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-3-carboxamide 885470-49-5P, [1-[3-Ethyl-7-[(4-methylpyrimidin-2-yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidin-4-yl]methanol 885470-50-8P, 3-Ethyl-N-(4-methylpyrimidin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-51-9P 885470-52-0P 885470-54-2P
885470-55-3P, 5-(1,4-Diazepan-1-yl)-3-methyl-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-56-4P 885470-57-5P 885470-58-6P,
3-Ethyl-N-(4-methylphenyl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885470-59-7P 885470-60-0P, 3-Ethyl-N-methyl-N'-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine

885470-61-1P, N-(2-Aminoethyl)-3-ethyl-N'-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885470-62-2P 885470-63-3P, 1-(2-Ethoxyethyl)-3-ethyl-N-(6-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-64-4P 885470-65-5P, 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-66-6P 885470-67-7P
 885470-68-8P 885470-69-9P, 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-70-2P 885470-71-3P
 885470-72-4P 885470-73-5P 885470-74-6P, 5-(3,4-Dimethylpiperazin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-75-7P 885470-76-8P, N-(1-Benzylpyrrolidin-3-yl)-1-(2-ethoxyethyl)-3-ethyl-N-methyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885470-77-9P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(4-methylpyridin-2-yl)-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885470-78-0P, N-(1-Benzylpyrrolidin-3-yl)-1-(2-ethoxyethyl)-3-ethyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-79-1P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-80-4P, Ethyl 4-[[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]piperidine-1-carboxylate 885470-81-5P, 1-(2-Ethoxyethyl)-3-ethyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-7-amine 885470-82-6P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(5-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-83-7P, 1-(2-Ethoxyethyl)-3-ethyl-N-(5-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-84-8P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-85-9P 885470-86-0P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(6-ethylpyridin-2-yl)-N-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-87-1P, N'-(4,6-Dimethylpyridin-2-yl)-1-(2-ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-88-2P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(6-ethylpyridin-2-yl)-N-methyl-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-89-3P, N'-(4,6-Dimethylpyridin-2-yl)-1-(2-ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-90-6P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(3-methylphenyl)-N-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-91-7P 885470-92-8P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(3-methylphenyl)-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-93-9P, 1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-95-1P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885470-96-2P, 1-(2-Ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-97-3P 885470-98-4P, 3-Methyl-N-(4-methylpyridin-2-yl)-5-(piperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885470-99-5P, 3-Methyl-5-(piperazin-1-yl)-N-(pyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-00-1P, 3-Methyl-5-(4-methylpiperazin-1-yl)-N-(6-methylpyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-01-2P, 3-Methyl-5-(4-methylpiperazin-1-yl)-N-(pyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-02-3P, 3-Methyl-5-(4-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-03-4P

885471-04-5P 885471-05-6P 885471-06-7P,
1-(2-Ethoxyethyl)-3-ethyl-N-(3-methylpyridin-2-yl)-5-(piperazin-1-yl)-1H-
pyrazolo[4,3-d]pyrimidin-7-amine 885471-07-8P,
1-(2-Ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(piperazin-1-yl)-1H-
pyrazolo[4,3-d]pyrimidin-7-amine 885471-08-9P,
5-[[1-(2-Ethoxyethyl)-3-ethyl-5-(piperazin-1-yl)-1H-pyrazolo[4,3-
d]pyrimidin-7-yl]amino]pyridin-2(1H)-one 885471-09-0P,
1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-phenyl-1H-
pyrazolo[4,3-d]pyrimidin-7-amine 885471-10-3P,
1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-N-(3-methylpyridin-2-
yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-11-4P
885471-12-5P, 1-(2-Ethoxyethyl)-3-ethyl-N-phenyl-5-(piperazin-1-
yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-13-6P
885471-15-8P, 5-[[1-(2-Ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-
yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]pyridin-2(1H)-one
885471-17-0P 885471-19-2P, 1-(2-Ethoxyethyl)-3-ethyl-N-
(3-methoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-
amine 885471-21-6P, N-(3-Chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-
5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-23-8P, 1-(2-Ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-
(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-24-9P
, 1-(2-Ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(4-methylpiperazin-1-yl)-
1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-26-1P,
N-(3-Chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(4-methylpiperazin-1-yl)-1H-
pyrazolo[4,3-d]pyrimidin-7-amine 885471-28-3P,
5-[4-(2-Aminoethyl)piperazin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(pyridin-2-
yl)-N-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-30-7P,
5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-
yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-32-9P,
1-(2-Ethoxyethyl)-3-ethyl-N'-(6-methylpyridin-2-yl)-N-[2-(morpholin-4-
yl)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-34-1P
885471-36-3P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-
N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-38-5P
, 5-[4-(2-Aminoethyl)piperazin-1-yl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-
methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-40-9P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-
N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-41-0P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(4-methylpyridin-2-yl)-
N-[2-(morpholin-4-yl)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-42-1P, 5-[4-(2-Aminoethyl)piperazin-1-yl]-1-(2-ethoxyethyl)-
3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-7-amine
885471-43-2P, 5-[4-(Aminomethyl)piperidin-1-yl]-1-(2-ethoxyethyl)-
3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-44-3P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(4-methylpyridin-2-yl)-
N-(piperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-45-4P, 5-[4-(Aminomethyl)piperidin-1-yl]-1-(2-ethoxyethyl)-
3-ethyl-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-46-5P, 5-[4-(Aminomethyl)piperidin-1-yl]-1-(2-ethoxyethyl)-
3-ethyl-N-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
885471-47-6P 885471-48-7P, 1-(2-Ethoxyethyl)-3-ethyl-N-
piperidin-4-yl-N'-pyridin-2-yl-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine
885471-49-8P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(6-methylpyridin-2-yl)-
N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine
885471-50-1P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-ethylpiperidin-4-yl)-
N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-51-2P, 1-(2-Ethoxyethyl)-3-ethyl-N-[(piperidin-4-yl)methyl]-
N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-52-3P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-ethylpiperidin-4-yl)-
N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-53-4P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-ethylpiperidin-4-yl)-
N'-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
885471-54-5P, 1-(2-Ethoxyethyl)-3-ethyl-N'-(6-methylpyridin-2-yl)-
N-(piperidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine

885471-55-6P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-isopropylpiperidin-4-yl)-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885471-56-7P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-isopropylpiperidin-4-yl)-N'-(pyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885471-57-8P, 1-(2-Ethoxyethyl)-3-ethyl-N-(1-isopropylpiperidin-4-yl)-N'-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine
 885471-58-9P, 1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(6-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxamide
 885471-59-0P, 1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxamide
 885471-60-3P, 1-[1-(2-Ethoxyethyl)-3-ethyl-7-[(pyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxamide
 885471-61-4P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885471-62-5P, 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-phenyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-63-6P,
 5-(4-Aminopiperidin-1-yl)-N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-64-7P,
 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-65-8P,
 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-66-9P,
 1-(2-Ethoxyethyl)-3-ethyl-N'-phenyl-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidin-5,7-diamine 885471-67-0P,
 1-(2-Ethoxyethyl)-3-ethyl-N'-(3-fluorophenyl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-68-1P,
 1-(2-Ethoxyethyl)-3-ethyl-N'-(3-methoxyphenyl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-69-2P,
 1-(2-Ethoxyethyl)-3-ethyl-N'-(4-fluorophenyl)-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-70-5P,
 N'-(3-Chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-N-[(piperidin-4-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 885471-71-6P
 885471-72-7P 885471-73-8P 885471-74-9P
 885471-75-0P 885471-76-1P 885471-77-2P,
 1-(2-Ethoxyethyl)-3-methyl-5-(4-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-78-3P,
 5-(4-Aminopiperidin-1-yl)-1-(2-ethoxyethyl)-3-methyl-N-(6-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-79-4P
 885471-80-7P 885471-81-8P 885471-82-9P
 885471-83-0P 885471-84-1P 885471-85-2P
 885471-86-3P 885471-87-4P 885471-88-5P
 885471-89-6P 885471-90-9P 885471-91-0P
 885471-93-2P 885471-94-3P 885471-95-4P
 885471-96-5P 885471-97-6P, 1-(2-Ethoxyethyl)-5-(4-ethylpiperazin-1-yl)-3-(methoxymethyl)-N-(pyrimidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885471-98-7P 885471-99-8P
 885472-00-4P 885472-01-5P 885472-02-6P
 885472-04-8P 885472-06-0P 885472-10-6P
 885472-12-8P 885472-14-0P 885472-16-2P
 885472-18-4P 885472-20-8P 885472-22-0P
 885472-24-2P 885472-26-4P 885472-28-6P
 885472-29-7P 885472-31-1P, 5-(Piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885472-32-2P 885472-33-3P 885472-34-4P,
 3-[(Cyclopropylmethoxy)methyl]-5-(piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885472-35-5P 885472-36-6P 885472-37-7P,
 5-(Piperazin-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(3,3,3-trifluoropropoxy)methyl]-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885472-38-8P, 5-(1,4-Diazepan-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
 885472-39-9P, 5-(1,4-Diazepan-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-

fluorophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 885472-40-2P
 885472-41-3P, 3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(
 pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
 d]pyrimidine-5,7-diamine 885472-42-4P 885472-43-5P
 885472-44-6P, 2-[4-[3-Ethyl-7-[(pyrimidin-4-yl)amino]-1-[2-(2,2,2-
 trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperazin-1-
 yl]ethanol 885472-45-7P, 5-(1,4-Diazepan-1-yl)-3-ethyl-N-
 (pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-
 d]pyrimidin-7-amine 885472-46-8P, 3-Ethyl-5-(4-methyl-1,4-
 diazepan-1-yl)-N-(pyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-
 pyrazolo[4,3-d]pyrimidin-7-amine 885472-47-9P
 885472-48-0P 885472-49-1P, [1-[3-Ethyl-7-[(pyrimidin-4-
 yl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-
 yl]piperidin-4-yl]methanol 885472-50-4P 885472-51-5P,
 1,3-Bis(2-Ethoxyethyl)-N,N-dimethyl-N'-(4-methylpyridin-2-yl)-1H-
 pyrazolo[4,3-d]pyrimidine-5,7-diamine 885473-18-7P
 885473-19-8P 885473-20-1P 885473-21-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(PDE5 inhibitor; preparation of pyrazolopyrimidines as PDE5 inhibitors for
 treating hypertension)

RN 792969-22-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-
 piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-47-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-
 piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-86-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-60-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-61-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 794511-62-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885469-95-4 CAPLUS

CN 4-Piperidinemethanol, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885469-96-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885469-97-6 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885469-98-7 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-fluorophenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 885469-99-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-(hexahydro-1H-1,4-diazepin-1-yl)-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl

RN 885470-00-8 CAPLUS


CN 4-Piperidinemethanol, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-fluorophenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 885470-01-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 885470-02-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-03-1 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-04-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-05-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-06-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 792969-47-2

CMF C20 H26 F3 N9 O

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 885470-08-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-09-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-4-pyrimidinyl-5-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-10-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(4-morpholinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-11-1 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-12-2 CAPLUS

CN 1-Piperazineethanol, 4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-13-3 CAPLUS


CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-14-4 CAPLUS


CN 3-Piperidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-15-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-16-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-17-7 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, hydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-18-8 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-19-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(4-ethyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-20-2 CAPLUS


CN Piperazine, 1-acetyl-4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-21-3 CAPLUS

CN Piperazine, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-4-(ethylsulfonyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-22-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3,4-dimethyl-1-piperazinyl]-3-ethyl-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885470-24-6 CAPLUS

CN Carbamic acid, [2-[[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 885470-23-5

CMF C22 H30 F3 N9 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 885470-25-7 CAPLUS


CN 1-Piperazinemethanol, 4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-26-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-pyrazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-27-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-pyrazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-28-0 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-(pyrazinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-29-1 CAPLUS

CN 4-Piperidinemethanol, 1-[3-ethyl-7-(pyrazinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-30-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(1-piperazinyl)-N-pyrazinyl-


1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-31-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-32-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-33-7 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-34-8 CAPLUS


CN 4-Piperidinemethanol, 1-[3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-35-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-36-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885470-37-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-38-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-[(6-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-39-3 CAPLUS


CN 4-Piperidinemethanol, 1-[3-ethyl-7-[(6-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-40-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-41-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-fluorophenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 885470-42-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885470-43-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-(2-pyridinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-44-0 CAPLUS
 CN 4-Piperidinemethanol, 1-[3-ethyl-7-(2-pyridinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-45-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885470-46-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N7-(4-fluorophenyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 885470-47-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-48-4 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-ethyl-7-[(4-methyl-2-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-49-5 CAPLUS


CN 4-Piperidinemethanol, 1-[3-ethyl-7-[(4-methyl-2-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-50-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methyl-2-pyrimidinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-51-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-52-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 792969-22-3

CMF C19 H24 F3 N9 O

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 885470-54-2 CAPLUS


CN 3-Piperidinemethanol, 1-[3-methyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-55-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(hexahydro-1H-1,4-diazepin-1-yl)-3-methyl-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885470-56-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(hexahydro-1H-1,4-diazepin-1-yl)-3-methyl-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 885470-55-3

CMF C19 H24 F3 N9 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 885470-57-5 CAPLUS


CN 4-Piperidinemethanol, 1-[3-methyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-58-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methylphenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 885470-59-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methylphenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885470-60-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N7-(4-methylphenyl)-N5-(1-methyl-4-piperidiny)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 885470-61-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminoethyl)-3-ethyl-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-62-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-63-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-65-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-pyridinyl)-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-70-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-71-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(6-ethyl-2-pyridinyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-72-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-73-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-74-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,4-dimethyl-1-piperazinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-75-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-(1-methyl-4-piperidiny)-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-76-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[1-(phenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-77-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-(1-methyl-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-78-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-[1-(phenylmethyl)-3-pyrrolidiny]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-79-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-80-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-81-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(1-piperazinyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-82-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-83-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-86-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(6-ethyl-2-pyridinyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-87-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-88-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(6-ethyl-2-pyridinyl)-N5-methyl-N5-(1-methyl-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-89-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-90-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(3-methylphenyl)-N5-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 885470-91-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-methylphenyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885470-92-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(3-methylphenyl)-N5-(1-methyl-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 885470-93-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-95-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidiny)-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-96-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-97-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-98-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885470-99-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-00-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-(4-methyl-1-piperazinyl)-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-01-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-(4-methyl-1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-02-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-03-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-04-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885471-05-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885471-06-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885471-07-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 885471-08-9 CAPLUS

CN 2(1H)-Pyridinone, 5-[[[1-(2-ethoxyethyl)-3-ethyl-5-(1-piperazinyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 885471-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 885471-10-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-N-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-11-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885471-12-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-phenyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 885471-13-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885471-15-8 CAPLUS


CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 885471-17-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 885471-19-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 885471-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 885471-23-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 885471-24-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)-5-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 885471-26-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-5-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 885471-28-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(2-aminoethyl)-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-30-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-32-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(6-methyl-2-pyridinyl)-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-34-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-36-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-38-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(2-aminoethyl)-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-40-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidiny1)-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-41-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-42-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(2-aminoethyl)-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-43-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(aminomethyl)-1-piperidinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-44-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-45-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(aminomethyl)-1-piperidinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-46-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(aminomethyl)-1-piperidinyl]-1-(2-ethoxyethyl)-3-ethyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-47-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(4-methyl-2-pyridinyl)-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-48-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-4-piperidinyl-N7-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-49-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(6-methyl-2-pyridinyl)-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-50-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-(1-ethyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-51-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-(4-piperidinylmethyl)-N7-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-52-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-(1-


ethyl-4-piperidinyl)-N7-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-53-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-(1-ethyl-4-piperidinyl)-N7-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-54-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(6-methyl-2-pyridinyl)-N5-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-55-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-[1-(1-methylethyl)-4-piperidinyl]-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-56-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-[1-(1-methylethyl)-4-piperidinyl]-N7-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-57-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-[1-(1-methylethyl)-4-piperidinyl]-N7-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-58-9 CAPLUS


CN 4-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(6-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-59-0 CAPLUS


CN 4-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-60-3 CAPLUS


CN 4-Piperidinecarboxamide, 1-[1-(2-ethoxyethyl)-3-ethyl-7-(2-pyridinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 885471-61-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 885471-62-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 885471-63-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-N-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl- (9CI) (CA INDEX NAME)




RN 885471-64-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 885471-65-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 885471-66-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-phenyl-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 885471-67-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(3-fluorophenyl)-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 885471-68-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(3-methoxyphenyl)-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 885471-69-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N7-(4-fluorophenyl)-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 885471-70-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(3-chlorophenyl)-1-(2-ethoxyethyl)-3-ethyl-N5-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 885471-71-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-72-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-(4-methyl-1-piperazinyl)-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-73-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-(4-methyl-1-piperazinyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-74-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-(1-piperazinyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-75-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-76-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-77-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-78-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-(2-ethoxyethyl)-3-methyl-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-79-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-80-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-81-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-82-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-83-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-84-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-85-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-N-(4-fluorophenyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885471-86-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885471-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 885471-88-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-89-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(ethoxymethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-90-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-(methoxymethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-N-(6-ethyl-2-pyridinyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-N-(6-ethyl-2-pyridinyl)-3-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-95-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(6-ethyl-2-pyridinyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-96-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-(2-propoxyethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-97-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-5-(4-ethyl-1-piperazinyl)-3-(methoxymethyl)-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-98-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885471-99-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(ethoxymethyl)-N-(6-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(ethoxymethyl)-1-(2-propoxyethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-01-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-02-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(6-ethyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-04-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-03-7

CMF C21 H28 F3 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 885472-06-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(ethoxymethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-05-9

CMF C21 H26 F3 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-10-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(ethoxymethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-09-3

CMF C20 H26 F3 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-12-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(ethoxymethyl)-5-(4-methyl-1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-11-7

CMF C21 H28 F3 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 885472-14-0 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-3-(ethoxymethyl)-N5-methyl-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 885472-13-9
 CMF C21 H30 F3 N9 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 885472-16-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-(ethoxymethyl)-N7-4-pyrimidinyl-N5-(2,2,6,6-tetramethyl-4-piperidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-15-1
 CMF C25 H36 F3 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-18-4 CAPLUS

CN 4-Piperidinol, 1-[3-(ethoxymethyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 885472-17-3

CMF C21 H27 F3 N8 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 885472-20-8 CAPLUS
 CN 4-Piperidinemethanol, 1-[3-(ethoxymethyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 885472-19-5
 CMF C22 H29 F3 N8 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 885472-22-0 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-[(1-methylethoxy)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-21-9
 CMF C22 H30 F3 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 885472-24-2 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[(1-methylethoxy)methyl]-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-23-1

CMF C26 H36 F3 N9 O4




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 885472-26-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-[(1-methylethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 885472-25-3
CMF C21 H28 F3 N9 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 885472-28-6 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(3,3,3-trifluoropropoxy)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 885472-27-5
CMF C22 H27 F6 N9 O2

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 885472-29-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-31-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-32-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(2,2,2-trifluoroethoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-33-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-[(cyclopropylmethoxy)methyl]-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-34-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-[(cyclopropylmethoxy)methyl]-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-35-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-[(cyclopropylmethoxy)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-36-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-3-[(4,4,4-trifluorobutoxy)methyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-37-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-3-[(3,3,3-trifluoropropoxy)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-38-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-(hexahydro-1H-1,4-diazepin-1-yl)-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-39-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-(hexahydro-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 885472-40-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-(4-fluorophenyl)-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 885472-41-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-42-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-43-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-4-pyrimidinyl-5-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-44-6 CAPLUS

CN 1-Piperazineethanol, 4-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-45-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(hexahydro-1H-1,4-diazepin-


1-yl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-46-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-47-9 CAPLUS

CN 3-Pyrrolidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-48-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3,4-dimethyl-1-piperazinyl]-3-ethyl-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-49-1 CAPLUS


CN 4-Piperidinemethanol, 1-[3-ethyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-50-4 CAPLUS


CN 3-Piperidinecarboxamide, 1-[3-methyl-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885472-51-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1,3-bis(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-18-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(1-piperazinyl)-N-pyrazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-19-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidiny1)-N7-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-20-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-21-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-fluorophenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 885473-22-3P 885473-23-4P 885473-24-5P

885473-25-6P 885473-26-7P 885473-28-9P

885473-29-0P 885473-30-3P 885473-31-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE5 inhibitor; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)

RN 885473-22-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-23-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-(1-piperazinyl)-N-2-pyridinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-24-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N7-(4-fluorophenyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 885473-25-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-26-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methyl-2-pyrimidinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI)
(CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 885473-28-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methylphenyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 885473-29-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-N-(4-methylphenyl)-5-[(3R)-3-methyl-1-piperazinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 885473-30-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N7-(4-methylphenyl)-N5-(1-methyl-4-piperidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 885473-31-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(3-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792968-79-7P, [5-Dimethylamino-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol


866923-52-6P, 5-Dimethylamino-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)

RN 792968-79-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



RN 866923-52-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

GI



AB Title compds. I [R1 = (un)substituted independently Ph, naphthyl, heteroaryl, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alk(en/yn)yl, cycloalkyl; or NR3R4 = (un)substituted mono- or polycyclyl containing at least one heteroatom; R5 = halo/cyclo/alkyl, alkenyl, alkynyl; R6, which may be attached at N1 or N2 of the pyrazole ring = H, cycloalkyl, alk(en/yn)yl, etc.; and their tautomers, and their pharmaceutically acceptable salts] were prepared as phosphodiesterase 5 (PDE5) inhibitors. Thus, amination of 5,7-dichloro-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidine with 2-amino-4-picoline, followed by a second amination of 5-chloro intermediate with 4-piperidinemethanol gave pyrazolopyrimidine II. In a scintillation proximity PDE5 assay, II inhibited PDE5 with an IC50 value of 0.0728 nM.

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:151143 CAPLUS

DOCUMENT NUMBER: 144:219321

TITLE: Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor

INVENTOR(S): Hughes, Bernadette

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2006016262 | A1 | 20060216 | WO 2005-IB2457 | 20050729 |
| WO 2006016262 | A8 | 20060629 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 AU 2005270904 A1 20060216 AU 2005-270904 20050729
 NO 2006006059 A 20070129 NO 2006-6059 20061229
 PRIORITY APPLN. INFO.: GB 2004-17777 A 20040810
 US 2004-606302P P 20040831
 WO 2005-IB2457 W 20050729


IT 792969-47-2 853003-47-1 853003-48-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (combination of selective noradrenaline reuptake inhibitor and PDEV
 inhibitor in treatment of pain)
 RN 792969-47-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-
 piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry..



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853003-47-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[methyl(1-
 methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-
 (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-48-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

AB The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phosphodiesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain. For example, the combination of i.p. (S,S)-reboxetine succinate and s.c. PDEV inhibitor 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulfonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (Compound A) displayed synergy in animal models of pain. Following single administration both (S,S)-reboxetine and Compound A produced a dose dependent anti-allodynic effect in the preclin. model of chronic pain.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1130641 CAPLUS

DOCUMENT NUMBER: 143:387058

TITLE: Preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V

INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Lu, Hwang-Fun; Marsh, Ian Roger; Morrell, Andrew Ian; Owen, Dafydd Rhys; Palmer, Michael John; Rogers, Thomas Edward; Windslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2005097799 | A1 | 20051020 | WO 2005-IB891 | 20050330 |
| WO 2005097799 | A8 | 20060216 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

CA 2562251 A1 20051020 CA 2005-2562251 20050330
 EP 1742950 A1 20070117 EP 2005-718362 20050330

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

GB 2004-7927 A 20040407
 GB 2004-7946 A 20040407
 US 2004-572024P P 20040518
 US 2004-572049P P 20040518
 WO 2005-IB891 W 20050330

OTHER SOURCE(S): MARPAT 143:387058


IT 866922-33-0P 866922-37-4P 866922-39-6P
 866922-41-0P 866922-43-2P 866922-45-4P
 866922-48-7P 866922-49-8P 866922-51-2P
 866922-52-3P 866922-53-4P 866922-56-7P
 866922-59-0P 866922-62-5P 866922-66-9P
 866922-70-5P 866922-73-8P 866922-76-1P
 866922-81-8P 866922-84-1P 866922-87-4P
 866922-89-6P 866922-91-0P 866922-93-2P
 866922-94-3P 866922-95-4P 866922-96-5P
 866922-97-6P 866922-98-7P 866922-99-8P
 866923-00-4P 866923-01-5P 866923-02-6P
 866923-03-7P 866923-04-8P 866923-05-9P
 866923-06-0P 866923-07-1P 866923-08-2P
 866923-09-3P 866923-11-7P 866923-13-9P
 866923-15-1P 866923-17-3P 866923-19-5P
 866923-21-9P 866923-23-1P 866923-25-3P
 866923-27-5P 866923-29-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of
 phosphodiesterase V)

RN 866922-33-0 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-
 methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI)
 (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-37-4 CAPLUS

CN Methanesulfonamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-
 pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA


INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-39-6 CAPLUS


CN Methanesulfonamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-41-0 CAPLUS


CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-43-2 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-2-hydroxy- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-45-4 CAPLUS


CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-48-7 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-49-8 CAPLUS


CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-51-2 CAPLUS


CN Propanamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-52-3 CAPLUS


CN Propanamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-53-4 CAPLUS


CN Propanamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-56-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 866922-59-0 CAPLUS

CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-62-5 CAPLUS
 CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]-N-methyl- (9CI)
 (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-66-9 CAPLUS
 CN Acetamide, N-[[1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]-N-methyl- (9CI)
 (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 866922-70-5 CAPLUS
 CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-73-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-pyrazinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-76-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(4-methyl-1-piperazinyl)methyl]-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-81-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-84-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[[(3S)-3-methoxy-1-pyrrolidinyl]methyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-89-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[[(3R)-3-methoxy-1-pyrrolidinyl]methyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[[(1-methylethyl)amino]methyl]-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-[(propylamino)methyl]-, hydrochloride (9CI)
(CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(1-pyrrolidinylmethyl)-, hydrochloride (9CI)
(CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-95-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-96-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(5-methyl-2-pyridinyl)-3-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-97-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-[(dimethylamino)methyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-98-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[[2-methoxyethyl)amino]methyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866922-99-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(4-morpholinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-01-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[(ethylamino)methyl]-N5,N5-dimethyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-02-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-[[2-methoxyethyl)amino]methyl]-N5,N5-dimethyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-03-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-[(diethylamino)methyl]-1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-04-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-3-[(methylamino)methyl]-N7-4-pyrimidinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-05-9 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-[(methylamino)methyl]-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-06-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5-methyl-3-[(methylamino)methyl]-N7-(4-methyl-2-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-07-1 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-[(methylamino)methyl]-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-08-2 CAPLUS


CN Acetamide, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-N-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-09-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(1-piperazinylmethyl)-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 866923-11-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1-piperazinyl)-3-(1-piperazinylmethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-10-6

CMF C22 H30 F3 N11 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-13-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-3-(4-morpholinylmethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-12-8

CMF C23 H31 F3 N10 O2


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 866923-15-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(4-morpholinylmethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 866923-14-0
CMF C22 H29 F3 N10 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 866923-17-3 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-ethyl-N5-methyl-N7-4-pyrimidinyl-3-(4-thiomorpholinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-16-2
CMF C21 H28 F3 N9 O S




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-19-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-3-(1-piperidinylmethyl)-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-18-4

CMF C24 H33 F3 N10 O


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 866923-21-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-3-(4-thiomorpholinylmethyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-20-8
CMF C23 H31 F3 N10 O S


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 866923-23-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R)-3-methyl-1-piperazinyl]-3-[(4-methyl-1-piperazinyl)methyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

Absolute stereochemistry.



CM 2

$$\begin{array}{c} \text{F} \\ | \\ \text{F}-\text{C}-\text{CO}_2\text{H} \\ | \\ \text{F} \end{array}$$

CM 1


CCN(CC)C1=CN2C(=N1)N(CCN2CCOCCF)N(CCN3CCNCC3)C4=CN(CCC4)N

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 866923-27-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-[(1,1-dioxido-4-thiomorpholinyl)methyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-26-4

CMF C23 H31 F3 N10 O3 S

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 866923-29-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanamine, 5-(1-piperazinyl)-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-N-(2,2,2-trifluoroethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 866923-28-6

CMF C20 H24 F6 N10 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 792968-79-7P 866923-50-4P 866923-51-5P

866923-52-6P 866923-53-7P 866923-54-8P


866923-55-9P 866923-56-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V)


RN 792968-79-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-50-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-51-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 866923-52-6 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-53-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-54-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxaldehyde, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-55-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 866923-56-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]methyl]-7-(4-pyrimidinylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB Title compds. I [R1 = cycloalkyl, cycloalkenyl, 5-6 membered heteroarom. ring, etc.; R2 = H, alkyl; R3-4 = alk(en/yn)yl, cycloalkyl, etc.; R5 = amino, alkylenylamino, etc.; R6 = alkyl, haloalkyl, alkenyl, alkynyl, etc.] are prepared For instance II is prepared in 12 steps from di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate, 2-ethoxyethyl bromide, 2-amino-4-methylpyridine, dimethylaminoacetic acid and dimethylamine. II has an IC50 = 1.12 for phosphodiesterase 5 (PDE5). I are useful for the treatment of diabetes and hypertension.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:472160 CAPLUS

DOCUMENT NUMBER: 143:26628
 TITLE: Preparation of pyrazolopyrimidines as cyclic guanylate monophosphate-specific phosphodiesterase type 5 inhibitors
 INVENTOR(S): Bell, Andrew; Brown, David; Bull, David; Fox, David; Marsh, Ian; Morrell, Andrew; Palmer, Michael; Winslow, Carol
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2005049617 | A1 | 20050602 | WO 2004-IB3791 | 20041119 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2545196 | A1 | 20050602 | CA 2004-2545196 | 20041119 |
| EP 1689752 | A1 | 20060816 | EP 2004-798915 | 20041119 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | |
| BR 2004016678 | A | 20070213 | BR 2004-16678 | 20041119 |
| PRIORITY APPLN. INFO.: | | | GB 2003-27323 | A 20031124 |
| | | | WO 2004-IB3791 | W 20041119 |

OTHER SOURCE(S): MARPAT 143:26628
 IT 852873-38-2P 852873-39-3P 852873-40-6P
 852873-41-7P 852873-42-8P 852873-43-9P
 852873-44-0P 852873-45-1P 852873-46-2P
 852873-47-3P 852873-48-4P 852873-49-5P
 852873-50-8P 852873-51-9P 852873-52-0P
 852873-53-1P 852873-54-2P 852873-55-3P
 852873-56-4P 852873-57-5P 852873-58-6P
 852873-59-7P 852873-60-0P 852873-61-1P
 852873-62-2P 852873-63-3P 852873-64-4P
 852873-65-5P 852873-66-6P 852873-67-7P
 852873-68-8P 852873-69-9P 852873-70-2P
 852873-71-3P 852873-72-4P 852873-73-5P
 852873-74-6P 852873-75-7P 852873-76-8P
 852873-77-9P 852873-78-0P 852873-79-1P
 852873-80-4P 852873-81-5P 852873-82-6P
 852873-83-7P 852873-84-8P 852873-85-9P
 852873-86-0P 852873-87-1P 852873-88-2P
 852873-89-3P 852873-90-6P 852873-91-7P
 852873-92-8P 852873-93-9P 852873-94-0P
 852873-96-2P 852873-97-3P 852873-98-4P
 852873-99-5P 852874-00-1P 852874-01-2P
 852874-02-3P 852874-03-4P 852874-04-5P
 852874-05-6P 852874-06-7P 852874-07-8P
 852874-08-9P 852874-09-0P 852874-10-3P
 852874-11-4P 852874-12-5P 852874-13-6P
 852874-14-7P 852874-15-8P 852874-16-9P

852874-17-0P 852874-18-1P 852874-19-2P


852874-20-5P 852874-21-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclic guanylate monophosphate-specific phosphodiesterase type 5 inhibitors)

RN 852873-38-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-39-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-methyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-40-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-41-7 CAPLUS


CN Pyrrolidine, 1-[[1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-pyrrolidinyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-42-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(methylamino)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-43-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-44-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-45-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-46-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-47-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylamino)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-48-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-49-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-50-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-[(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-51-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-52-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-53-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-N-[2-(methylamino)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-54-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-55-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-56-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-57-5 CAPLUS

CN Glycine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-58-6 CAPLUS

CN L-Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-59-7 CAPLUS

CN D-Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852873-60-0 CAPLUS

CN β -Alanine, N-[[5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-61-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
 (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-62-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852873-63-3 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-piperidinyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N,1-dimethyl-7-[(4-methyl-2-pyridinyl)amino]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-65-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N,N,1-trimethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-7-
[(4-methyl-2-pyridinyl)amino]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-5-
[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N,N-dimethyl-
5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-70-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N,1-dimethyl-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-71-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-72-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-methyl-5-[(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-73-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-N,1-dimethyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-74-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-75-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-76-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-77-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-1-methyl-5-[methyl (1-methylethyl) amino]-7-[(4-methyl-2-pyridinyl) amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-78-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-methyl-5-[methyl (1-methylethyl) amino]-7-[(4-methyl-2-pyridinyl) amino]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-79-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-methyl-N-(1-methyl-4-piperidinyl)-7-[(4-methyl-2-pyridinyl) amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-80-4 CAPLUS


CN Piperazine, 1-[[1-(2-ethoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-81-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-82-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-


ethoxyethyl)-N-(2-methoxyethyl)-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-83-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-84-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-ethyl-5-(ethylamino)-7-(pyrazinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-85-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylamino)-N-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-86-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-87-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylamino)-N-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852873-88-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 852873-89-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 852873-90-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylmethylamino)-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 852873-91-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-ethyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 852873-92-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-N-(1-methylethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-93-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-(2-


methoxyethyl)-5-(methylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-94-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(1-methylethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-96-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-hydroxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-97-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-(ethylamino)-1-(1-methylethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-98-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylamino)-N-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852873-99-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[(2-hydroxyethyl)methylamino]-N-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-00-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[(2-methoxyethyl)amino]-N-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-01-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-N-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-02-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3-[(methylamino)carbonyl]-1-(1-methylethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-03-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-5-(dimethylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 852874-04-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-5-(ethylamino)- (9CI) (CA INDEX NAME)



RN 852874-05-6 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 852874-06-7 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-methyl-5-[methyl(1-methyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)




RN 852874-07-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 852874-08-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[3-(methylamino)-1-azetidiny]- (9CI) (CA INDEX NAME)



RN 852874-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852874-10-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-N-methyl-5-[methyl[(3S)-1-methyl-3-pyrrolidinyl]amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 852874-11-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-5-[methyl[(3S)-1-methyl-3-pyrrolidinyl]amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-12-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-N-methyl-7-

[(4-methyl-2-pyridinyl)amino]-5-[[(3S)-1-methyl-3-pyrrolidinyl]amino]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-13-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 852874-14-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 852874-15-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-7-(cyclopentylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 852874-16-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-(ethylamino)- (9CI) (CA INDEX NAME)




RN 852874-17-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 852874-18-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(2-aminoethyl)-7-(cyclopentylamino)-5-(diethylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 852874-19-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-methyl-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 852874-20-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-N-(2-methoxyethyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 852874-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-methyl-1-(2-methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB The title compds. I [R1 = (un)substituted cycloalkyl, etc.; R2 = H, alkyl; R3, R4 = (un)substituted alkyl, alkenyl, etc.; R5 = YCONR15R16; Y = alkylene, etc.; R15, R16 = H, (un)substituted alkyl, etc.; R6, which may be attached at N1 or N2, is (un)substituted alkyl, alkenyl, etc.] are prepared. Thus, 1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-5-(pyrrolidin-1-yl)-3-(pyrrolidin-1-carbonyl)-1H-pyrazolo[4,3-d]pyrimidine was prepared from Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate and pyrrolidine. Compds. of this invention in vitro showed IC50 values of 0.02 nM to 2.95 nM against cyclic guanylate monophosphate-specific phosphodiesterase type 5.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:472159 CAPLUS

DOCUMENT NUMBER: 143:26627

TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines with phosphodiesterase-5 (PDE5) inhibiting activity
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Dack, Kevin Neil; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 282 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|------------------|------------|
| WO 2005049616 | A1 | 20050602 | WO 2004-IB3747 | 20041112 |
| WO 2005049616 | A8 | 20060601 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2004290643 | A1 | 20050602 | AU 2004-290643 | 20041112 |
| CA 2546987 | A1 | 20050602 | CA 2004-2546987 | 20041112 |
| EP 1689751 | A1 | 20060816 | EP 2004-798876 | 20041112 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU | | | |
| CN 1882591 | A | 20061220 | CN 2004-80034570 | 20041112 |
| NL 1027568 | A1 | 20050526 | NL 2004-1027568 | 20041123 |
| NL 1027568 | C2 | 20051130 | | |
| US 2005245544 | A1 | 20051103 | US 2004-997191 | 20041124 |
| NO 2006002950 | A | 20060823 | NO 2006-2950 | 20060623 |
| PRIORITY APPLN. INFO.: | | | GB 2003-27319 | A 20031124 |
| | | | US 2004-535797P | P 20040112 |
| | | | WO 2004-IB3747 | W 20041112 |

OTHER SOURCE(S): MARPAT 143:26627

IT 853003-28-8P 853003-29-9P 853003-30-2P
853003-31-3P 853003-32-4P 853003-33-5P
853003-34-6P 853003-35-7P 853003-36-8P
853003-37-9P 853003-38-0P 853003-39-1P
853003-40-4P 853003-41-5P 853003-42-6P
853003-43-7P 853003-44-8P 853003-45-9P
853003-46-0P 853003-47-1P 853003-48-2P
853003-49-3P 853003-50-6P 853003-51-7P
853003-52-8P 853003-53-9P 853003-54-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)

RN 853003-28-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-29-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(6-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-30-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-31-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-32-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(methylpropylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-33-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-34-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-35-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(cyclobutylmethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-36-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-37-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(2-methoxy-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-38-0 CAPLUS


CN 1,2,4-Oxadiazol-5(2H)-one, 3-[1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-39-1 CAPLUS


CN 1,2,4-Oxadiazol-5(2H)-one, 3-[1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853003-40-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 853003-41-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 853003-42-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)-5-(ethylmethylamino)- (9CI) (CA INDEX NAME)



RN 853003-43-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(cyclopropylmethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-44-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(cyclopropylmethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-45-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-46-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(1-methylethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-47-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-48-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-49-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-50-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-51-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-52-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-53-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-[2-(2,2-difluoroethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853003-54-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-[2-(2,2-difluoroethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 853004-42-9P 853004-52-1P 853004-53-2P


853004-60-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity)


RN 853004-42-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-52-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-53-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-60-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 853005-71-7P 853005-72-8P 853005-73-9P
 853005-74-0P 853005-75-1P 853005-76-2P
 853005-77-3P 853005-78-4P 853005-79-5P
 853005-80-8P 853005-81-9P 853005-82-0P
 853005-83-1P 853005-84-2P 853005-85-3P
 853005-86-4P 853005-87-5P 853005-88-6P
 853005-89-7P 853005-90-0P 853005-91-1P
 853005-92-2P 853005-93-3P 853005-94-4P
 853005-95-5P 853005-96-6P 853005-97-7P
 853005-98-8P 853005-99-9P 853006-00-5P
 853006-01-6P 853006-02-7P 853006-03-8P
 853006-04-9P 853006-05-0P 853006-06-1P
 853006-07-2P 853006-08-3P 853006-09-4P
 853006-10-7P 853006-11-8P 853006-12-9P
 853006-13-0P 853006-14-1P 853006-15-2P
 853006-16-3P 853006-17-4P 853006-18-5P
 853006-19-6P 853006-20-9P 853006-22-1P
 853006-23-2P 853006-24-3P 853006-25-4P
 853006-26-5P 853006-27-6P 853006-28-7P
 853006-29-8P 853006-30-1P 853006-31-2P
 853006-32-3P 853006-33-4P 853006-34-5P
 853006-35-6P 853006-36-7P 853006-37-8P
 853006-38-9P 853006-39-0P 853006-40-3P
 853006-41-4P 853006-42-5P 853006-43-6P
 853006-44-7P 853006-45-8P 853006-46-9P
 853006-47-0P 853006-48-1P 853006-49-2P
 853006-50-5P 853006-51-6P 853006-52-7P
 853006-53-8P 853006-54-9P 853006-55-0P
 853006-56-1P 853006-57-2P 853006-58-3P
 853006-59-4P 853006-60-7P 853006-61-8P
 853006-62-9P 853006-64-1P 853006-65-2P
 853006-66-3P 853006-67-4P 853006-68-5P
 853006-69-6P 853006-70-9P 853006-71-0P
 853006-72-1P 853006-73-2P 853006-74-3P
 853006-75-4P 853006-76-5P 853006-78-7P
 853006-79-8P 853006-82-3P 853006-83-4P
 853006-87-8P 853006-90-3P 853006-93-6P
 853006-96-9P 853006-99-2P 853007-01-9P
 853007-04-2P 853007-06-4P 853007-08-6P
 853007-11-1P 853007-13-3P 853007-16-6P
 853007-18-8P 853007-20-2P 853007-22-4P
 853007-24-6P 853007-25-7P 853007-26-8P
 853007-27-9P 853007-28-0P 853007-29-1P
 853007-30-4P 853007-31-5P 853007-32-6P
 853007-33-7P 853007-34-8P 853007-35-9P
 853007-36-0P 853007-37-1P 853007-38-2P
 853007-39-3P 853007-40-6P 853007-41-7P
 853007-42-8P 853007-43-9P 853007-44-0P
 853007-45-1P 853007-46-2P 853007-47-3P
 853007-49-5P 853007-50-8P 853007-51-9P
 853007-52-0P 853007-53-1P 853007-54-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5
 inhibiting activity)

RN 853005-71-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[(3R)-
 3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-72-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-73-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-7-[(4-methyl-2-pyridinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-74-0 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-75-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-76-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[(3S)-3-methoxy-1-pyrrolidinyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-77-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[(3R)-3-methoxy-1-pyrrolidinyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-78-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-79-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(2-methylpropyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-80-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-81-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(cyclopentylmethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-82-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethlamino)-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-83-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-84-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-methoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-85-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-86-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-87-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-88-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-89-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-90-0 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(pyrazinylamino)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-91-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(methylpropylamino)- (9CI) (CA INDEX NAME)



RN 853005-92-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclopentylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 853005-93-3 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclobutylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 853005-94-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclobutylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 853005-95-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclopropylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 853005-96-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclopropylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 853005-97-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(4-ethyl-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-98-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-ethyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-99-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylanilino)-7-[(6-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-00-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(6-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-01-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(4,5-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-5-(ethylmethlamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-02-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-7-[(4,5-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-03-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-5-(dimethylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 853006-04-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(ethylmethylamino)- (9CI) (CA INDEX NAME)




RN 853006-05-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 853006-06-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(ethylamino)- (9CI) (CA INDEX NAME)




RN 853006-07-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 853006-08-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-5-(diethylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 853006-09-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-(cyclohexylamino)-1-(2-ethoxyethyl)-5-(methylamino)- (9CI) (CA INDEX NAME)



RN 853006-10-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[(cyclopropylmethyl)propylamino]-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-11-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylpropyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-12-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[ethyl (2-methoxyethyl) amino]-7-[(4-methyl-2-pyridinyl) amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-13-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl) amino]-5-(2-methyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-14-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[[[(1S)-1-methylpropyl]amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-15-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[[[(1R)-1-methylpropyl]amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-16-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-17-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-18-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-19-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-20-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-22-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-23-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylamino)-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-24-3 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-25-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-26-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-27-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[[(3R)-tetrahydro-3-furanyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853006-28-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-(2-ethoxyethyl)-7-[[(3R)-tetrahydro-3-furanyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853006-29-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(cyclobutylmethylamino)-1-(2-ethoxyethyl)-7-[[(3R)-tetrahydro-3-furanyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853006-30-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(2-methoxy-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-31-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(2-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-32-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(2-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-33-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,6-dimethyl-4-pyrimidinyl)amino]-1-(2-ethoxyethyl)-5-(ethylmethylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-34-5 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 853006-35-6 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 853006-36-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-methyl-N5-(1-methylethyl)-N7-(4-methyl-2-pyridinyl)-3-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-37-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)-3-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-38-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(5-fluoro-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-39-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 853006-40-3 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 853006-41-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(6-methoxy-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-42-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 853006-43-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(3-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 853006-44-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 853006-45-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(3,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-

(9CI) (CA INDEX NAME)




RN 853006-46-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(3,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-
(9CI) (CA INDEX NAME)




RN 853006-47-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-
(9CI) (CA INDEX NAME)




RN 853006-48-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,3-difluorophenyl) amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl) amino]- (9CI) (CA INDEX NAME)




RN 853006-49-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl) amino]-7-[(3-methylphenyl) amino]- (9CI) (CA INDEX NAME)




RN 853006-50-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl) amino]-7-(phenylamino)- (9CI) (CA INDEX NAME)



RN 853006-51-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylanino)-7-[(4-methyl-2-pyridinyl) amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-52-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-ethyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-53-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(6-ethyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-54-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(6-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-55-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(2-fluoro-5-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 853006-56-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(2-fluoro-5-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 853006-57-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 853006-58-3. CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(2-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 853006-59-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-60-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(2-methoxyethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-61-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(3-methoxybutyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-62-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[(2R)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-64-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-65-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 853006-66-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-67-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-68-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[[4-(hydroxymethyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-69-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(cyclobutyloxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-70-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(6-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-71-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(cyclobutyloxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-72-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-7-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 853006-73-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-74-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-75-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-76-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(4-methyl-2-pyridinyl)amino]-5-(2-methyl-1-pyrrolidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-78-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(cyclobutylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-79-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-82-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA


INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-83-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-87-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853006-90-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[(2S)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853006-93-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 853006-96-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 853006-99-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 853007-01-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 853007-04-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-06-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-08-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-11-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-13-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-16-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-18-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-20-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 853007-22-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-24-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(methylpropylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-25-7 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI)
 (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-26-8 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-27-9 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[[4-(hydroxymethyl)-2-pyridinyl]amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-28-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(dimethylamino)-1-(2-ethoxyethyl)-N-(ethylsulfonyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-29-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-N-(ethylsulfonyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-30-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-1-(2-ethoxyethyl)-N-(ethylsulfonyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-31-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-methyl-4-pyrimidinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-32-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-1-(2-ethoxyethyl)-7-[(6-methyl-4-pyrimidinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853007-33-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethlamino)-7-[(4-fluoro-3-methylphenyl)amino]-N-(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 853007-34-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-N-(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 853007-35-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-N-(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 853007-36-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-37-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-[2-(cyclobutyloxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-38-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 1-[2-(cyclobutyloxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-39-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-40-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylanino)-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-41-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-[methyl(1-methylethyl)amino]-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-42-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, N-(ethylsulfonyl)-5-[methyl(1-


methylethyl)amino]-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-43-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-N-(methylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-44-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-N-(ethylsulfonyl)-1-(2-propoxyethyl)-7-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-45-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-(2-propoxyethyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-46-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-47-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-49-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(3,3,3-trifluoropropoxy)ethyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-50-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-51-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-52-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-53-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)-1-(2-propoxyethyl)- (9CI)' (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853007-54-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxamide, 5-(ethylmethylamino)-1-(2-hydroxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-N-(methylsulfonyl)- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 853004-35-0P 853004-36-1P 853004-38-3P

853004-39-4P 853004-40-7P 853004-41-8P

853004-43-0P 853004-44-1P 853004-45-2P

853004-46-3P 853004-47-4P 853004-48-5P

853004-49-6P 853004-50-9P 853004-51-0P

853004-54-3P 853004-55-4P 853004-56-5P

853004-57-6P 853004-58-7P 853004-59-8P

853004-61-2P 853004-62-3P 853004-63-4P

853004-64-5P 853004-65-6P 853004-66-7P

853005-51-3P 853005-52-4P 853005-53-5P

853005-54-6P 853005-55-7P 853005-56-8P

853005-57-9P 853005-58-0P 853005-59-1P

853005-60-4P 853005-61-5P 853005-62-6P

853005-63-7P 853005-64-8P 853005-65-9P

853005-66-0P 853005-67-1P 853005-68-2P

853005-69-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of diaminopyrazolopyrimidines with phosphodiesterase-5
inhibiting activity)

RN 853004-35-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-

(cyclopropylmethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-36-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[(2R)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-38-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(1-methylethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-39-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(3-methoxybutyl)-5-[(4-methyl-2-pyridinyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-40-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(5-fluoro-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-41-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-43-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(6-methoxy-2-pyridinyl)amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-44-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-45-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-46-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(3-fluorophenyl)amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-47-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-48-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-
 [methyl (1-methylethyl)amino]-7-[(2,4-difluorophenyl)amino]-, methyl
 ester (9CI) (CA INDEX NAME)




RN 853004-49-6 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-
 ethoxyethyl)-7-[(tetrahydro-2H-pyran-4-yl)amino]-, methyl ester (9CI) (CA
 INDEX NAME)



RN 853004-50-9 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(2-


methoxyethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-51-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(6-ethyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-54-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(6-ethyl-4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-55-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-7-(2-pyridinylamino)-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-56-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(3,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-57-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(3,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-58-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-59-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(2,3-difluorophenyl)amino]-1-(2-ethoxyethyl)-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-61-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(2-fluoro-5-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-62-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(2-fluoro-5-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-63-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(dimethylamino)-7-[(3,4-

dimethylphenyl) amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-64-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(3,4-dimethylphenyl) amino]-1-(2-ethoxyethyl)-5-(ethylmethylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-65-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(2-fluorophenyl) amino]-5-[methyl(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-66-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(cyclopropylmethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-51-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-(2-propoxyethyl)-7-(2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-52-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-(2-


propoxyethyl)-7-(2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-53-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-1-(2-propoxyethyl)-7-(2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-54-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 853005-55-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 853005-56-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 853005-57-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 853005-58-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 7-[(4-fluoro-3-methylphenyl)amino]-5-[methyl(1-methylethyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 853005-59-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(2,2-difluoroethoxy)ethyl]-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-60-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-61-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(2,2-difluoroethoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-62-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-63-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-64-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-65-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(ethylmethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-66-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[2-(3-fluoropropoxy)ethyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-67-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-(diethylamino)-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-68-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-5-(1-pyrrolidinyl)-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-69-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 1-[(2S)-2-methoxypropyl]-5-[methyl(1-methylethyl)amino]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB Title compds. [I; R1 = (substituted) cyclic group; R2 = H, alkyl; R3, R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R5 = YCO2R15, YR16; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Y = bond, CH2OCH2, alkylene, cycloalkylene; R15 = H, (substituted) alkyl; R16 = tetrazolyl, trifluoromethyltriazolyl, methylsulfonyltriazolyl, etc.; dotted lines = double bonds to form an aromatic ring], were prepared Thus, title compound (II) (preparation given) inhibited PDE-5 with IC50 = 0.075 nM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:965255 CAPLUS

DOCUMENT NUMBER: 141:410950

TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension

INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2004096810 | A1 | 20041111 | WO 2004-IB1433 | 20040422 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| AU 2004234158 | A1 | 20041111 | AU 2004-234158 | 20040422 |

| | | | | |
|---|----|----------|------------------|------------|
| CA 2523831 | A1 | 20041111 | CA 2004-2523831 | 20040422 |
| EP 1620437 | A1 | 20060201 | EP 2004-728868 | 20040422 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| BR 2004009903 | A | 20060425 | BR 2004-9903 | 20040422 |
| CN 1780841 | A | 20060531 | CN 2004-80011467 | 20040422 |
| JP 2006524636 | T | 20061102 | JP 2006-500346 | 20040422 |
| NL 1026074 | A1 | 20041101 | NL 2004-1026074 | 20040428 |
| NL 1026074 | C2 | 20050809 | | |
| US 2005043325 | A1 | 20050224 | US 2004-834484 | 20040429 |
| NO 2005004404 | A | 20051124 | NO 2005-4404 | 20050922 |
| PRIORITY APPLN. INFO.: | | | GB 2003-9780 | A 20030429 |
| | | | GB 2003-27748 | A 20031128 |
| | | | US 2003-476678P | P 20030606 |
| | | | US 2004-538147P | P 20040120 |
| | | | WO 2004-IB1433 | A 20040422 |

OTHER SOURCE(S): MARPAT 141:410950

IT 792966-67-7P 792966-68-8P 792966-69-9P
 792966-70-2P 792966-71-3P 792966-72-4P
 792966-73-5P 792966-74-6P 792966-75-7P
 792966-76-8P 792966-77-9P, 1-(2-Ethoxyethyl)-3-methyl-5-
 ((3R)-3-methylpiperazin-1-yl)-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-
 7-ylamine 792966-78-0P 792966-79-1P
 792966-80-4P 792966-81-5P, 1-(2-Ethoxyethyl)-3-ethyl-5-
 ((3R)-3-methylpiperazin-1-yl)-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-
 7-ylamine 792966-82-6P 792966-83-7P
 792966-84-8P 792966-85-9P 792966-86-0P
 792966-87-1P 792966-88-2P 792966-89-3P,
 1-(2-Isopropoxyethyl)-3-methyl-5-((3R)-3-methylpiperazin-1-yl)-N-pyrimidin-
 4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792966-90-6P
 792966-91-7P 792966-92-8P 792966-93-9P
 792966-94-0P 792966-95-1P 792966-96-2P
 792966-97-3P 792966-98-4P 792966-99-5P
 792967-00-1P 792967-01-2P 792967-02-3P
 792967-03-4P 792967-04-5P 792967-05-6P
 792967-06-7P 792967-07-8P 792967-09-0P
 792967-11-4P 792967-13-6P 792967-15-8P
 792967-17-0P 792967-19-2P 792967-21-6P
 792967-23-8P 792967-25-0P 792967-27-2P
 792967-29-4P 792967-31-8P 792967-33-0P
 792967-35-2P 792967-37-4P 792967-39-6P
 792967-41-0P 792967-43-2P 792967-45-4P
 792967-47-6P 792967-49-8P 792967-51-2P
 792967-53-4P 792967-54-5P 792967-56-7P
 792967-57-8P 792967-59-0P 792967-60-3P
 792967-61-4P 792967-62-5P 792967-64-7P
 792967-66-9P 792967-68-1P 792967-70-5P
 792967-72-7P 792967-73-8P 792967-74-9P
 792967-75-0P 792967-76-1P 792967-77-2P
 792967-78-3P 792967-79-4P 792967-80-7P
 792967-81-8P 792967-82-9P 792967-83-0P
 792967-84-1P 792967-85-2P 792967-86-3P
 792967-87-4P, 1-Methyl-5-((3R)-3-methylpiperazin-1-yl)-3-propyl-N-
 pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792967-88-5P
 792967-89-6P 792967-90-9P 792967-91-0P
 792967-92-1P 792967-93-2P 792967-94-3P
 792967-95-4P 792967-96-5P 792967-97-6P
 792967-98-7P 792967-99-8P 792968-00-4P
 792968-01-5P 792968-02-6P 792968-03-7P
 792968-04-8P 792968-05-9P 792968-06-0P
 792968-07-1P 792968-08-2P 792968-09-3P
 792968-10-6P 792968-11-7P 792968-12-8P
 792968-13-9P 792968-14-0P 792968-15-1P

792968-16-2P 792968-17-3P 792968-18-4P
792968-19-5P 792968-20-8P 792968-21-9P
792968-22-0P 792968-23-1P 792968-24-2P
792968-25-3P 792968-26-4P 792968-27-5P
792968-28-6P 792968-29-7P 792968-30-0P
792968-31-1P 792968-32-2P 792968-33-3P
792968-34-4P, 5-((2R,5S)-2,5-Dimethylpiperazin-1-yl)-1-(2-ethoxyethyl)-3-methyl-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792968-35-5P 792968-36-6P 792968-37-7P
, 5-((2R,5S)-2,5-Dimethylpiperazin-1-yl)-1-(2-ethoxyethyl)-3-ethyl-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792968-38-8P
792968-39-9P 792968-40-2P 792968-41-3P
792968-42-4P 792968-43-5P 792968-44-6P
792968-45-7P 792968-46-8P 792968-47-9P
792968-48-0P 792968-49-1P, 3-Ethyl-1-(2-methoxyethyl)-N'-(4-methylpyridin-2-yl)-N-[2-(pyrazol-1-yl)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-50-4P, (2S)-2-[[3-Ethyl-1-(2-methoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]propan-1-ol 792968-51-5P 792968-52-6P
792968-53-7P 792968-54-8P 792968-55-9P
792968-56-0P 792968-57-1P, 1-(2-Ethoxyethyl)-N-methyl-3-methyl-N'-(4-methylpyridin-2-yl)-N-((3S)-1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-58-2P,
1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(4-methylpyridin-2-yl)-N-((3S)-1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-59-3P, N-[3-Methyl-5-(piperazin-1-yl)-1-[(tetrahydropyran-2-yl)methyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methylpyridin-2-ylamine dihydrochloride 792968-60-6P 792968-61-7P
792968-62-8P 792968-63-9P 792968-64-0P
792968-65-1P 792968-66-2P 792968-75-3P,
N-[3-Isopropyl-1-(2-methoxyethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine bis(trifluoroacetate) 792968-76-4P, N-[3-Isopropyl-1-(2-methoxyethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methylpyridin-2-ylamine 792968-77-5P, N-[3-Ethyl-1-(2-methoxyethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-5-methyl-2H-pyrazol-3-ylamine 792968-78-6P, [1-(2-Ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol 792968-79-7P, [5-Dimethylamino-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol 792968-80-0P, N-[1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine dihydrochloride 792968-81-1P 792968-82-2P,
1-(2-Ethoxyethyl)-3-(methoxymethyl)-N,N-dimethyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-83-3P,
N-[1-(2-Ethoxyethyl)-3-(ethoxymethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine dihydrochloride 792968-84-4P 792968-85-5P, 1-(2-Ethoxyethyl)-3-(ethoxymethyl)-N,N-dimethyl-N'-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-86-6P 792968-87-7P,
N-[1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-(piperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine dihydrochloride 792968-88-8P
, 1-(2-Ethoxyethyl)-N-methyl-3-methyl-N-((3S)-1-methylpyrrolidin-3-yl)-N'-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-89-9P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N'-(5-methylpyridin-2-yl)-N-((3S)-1-methylpyrrolidin-3-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-90-2P, 1-(2-Ethoxyethyl)-3-ethyl-N-methyl-N-((3S)-1-methylpyrrolidin-3-yl)-N'-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792968-91-3P
792968-92-4P 792968-93-5P 792968-94-6P
792968-95-7P 792968-96-8P 792968-97-9P
792968-98-0P 792968-99-1P 792969-01-8P
792969-03-0P 792969-04-1P 792969-05-2P


792969-06-3P 792969-07-4P 792969-08-5P
 792969-09-6P, N-[1-(2-Ethoxyethyl)-3-methoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-10-9P 792969-11-0P 792969-12-1P
 792969-13-2P 792969-14-3P 792969-15-4P
 792969-16-5P 792969-17-6P 792969-18-7P
 792969-19-8P 792969-20-1P 792969-21-2P
 792969-22-3P, N-[3-Methyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine 792969-23-4P 792969-24-5P 792969-25-6P
 792969-26-7P 792969-27-8P, N-[5-[(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine monohydrochloride
 792969-28-9P, N-[5-[(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-3-methoxymethyl-1-(2-propoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-29-0P 792969-30-3P,
 N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine
 792969-31-4P 792969-32-5P 792969-33-6P
 792969-34-7P 792969-35-8P 792969-36-9P,
 N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-3-methyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-37-0P, N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-3-methyl-1-(2-propoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-38-1P 792969-39-2P
 792969-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE5 inhibitor; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792966-67-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-1-(2-methoxyethyl)-N5-methyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-68-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-69-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3-amino-1-azetidinyl)-1-(2-ethoxyethyl)-3-ethyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-70-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-71-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-3-(1-methylethyl)-

5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-72-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-73-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-74-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-3-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-75-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-1-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-76-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(3-methoxypropyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-77-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-78-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-79-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-(1-methylethyl)-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-80-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3S)-3-(1-methylethyl)-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-81-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-82-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-83-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3R)-3-

(1-methylethyl)-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-84-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-(1-methylethyl)-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-85-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-5-[(3S)-3-ethyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-86-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-1-[2-(1-methylethoxy)ethyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-87-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-88-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-pyrimidinyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-89-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-1-[2-(1-methylethoxy)ethyl]-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-90-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-1-(1-methylethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-91-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(3-ethoxypropyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-92-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-93-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-3-propyl-N-3-pyridazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-94-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-ethyl-N-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 792966-95-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(2,5-dimethyl-1-piperazinyl)-1-methyl-N-(5-methyl-2-pyridinyl)-3-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-96-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(2-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-97-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(3-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-98-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,5-dimethyl-1-piperazinyl)-1-methyl-N-(5-methyl-2-pyridinyl)-3-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792966-99-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(2,6-dimethyl-1-piperazinyl)-1-methyl-N-(5-methyl-2-pyridinyl)-3-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-00-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-01-2 CAPLUS


CN 4-Piperidinol, 1-[1-methyl-7-[(5-methyl-2-pyridinyl)amino]-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-02-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperidinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-03-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-3-azetidiny-1-methyl-N7-(5-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-04-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-3-azetidinyln-5,1-dimethyl-N7-(5-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-05-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[(3S)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-06-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-07-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(4-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N5-(1-methyl-4-piperidiny)-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-08-9

CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-11-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N5-(1-methyl-4-piperidiny1)-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 792967-10-3

CMF C22 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-13-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-(1-methyl-3-pyrrolidinyl)-3-propyl-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 792967-12-5

CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-15-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(4-amino-1-piperidinyl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-14-7

CMF C20 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792967-17-0 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(hexahydro-1H-1,4-diazepin-1-yl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-16-9
 CMF C20 H28 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 792967-19-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-18-1
 CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(4-methyl-2-pyridinyl)-N5-4-piperidinyl-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-20-5

CMF C20 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-23-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[3-(aminomethyl)-1-piperidinyl]-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-22-7

CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-25-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N5-[2-(methylamino)ethyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-24-9

CMF C18 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE.

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-27-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-26-1

CMF C18 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792967-29-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[4-(dimethylamino)-1-piperidinyl]-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-28-3
 CMF C22 H32 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 792967-31-8 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N5-[(1-methyl-3-piperidinyl)methyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-30-7
 CMF C22 H32 N8



RN 792967-35-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[2-[(dimethylamino)methyl]-1-piperidinyl]-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-34-1
 CMF C23 H34 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 792967-37-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(1-methyl-2-pyrrolidinyl)methyl]-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-36-3
 CMF C21 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-39-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-38-5

CMF C22 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792967-41-0 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-40-9
 CMF C19 H28 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 792967-43-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-42-1
 CMF C20 H30 N8




RN 792967-47-6 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[3-(dimethylamino)propyl]-
 N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI)
 (CA INDEX NAME)
 CM 1
 CRN 792967-46-5
 CMF C21 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 792967-49-8 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N5-[2-(methylamino)ethyl]-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)
 CM 1
 CRN 792967-48-7
 CMF C19 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-45-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[3-(dimethylamino)propyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-44-3

CMF C20 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-51-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(3-methyl-1-piperazinyl)-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-50-1

CMF C20 H28 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-53-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-N5-(3R)-3-pyrrolidinyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-52-3

CMF C19 H26 N8

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 792967-54-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-N5-[(3S)-3-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-56-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-55-6

CMF C22 H30 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 792967-57-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-4-piperidinyl-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792967-59-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 792967-58-9

CMF C20 H26 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 792967-60-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[4-(methyamino)-1-piperidinyl]-N-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-61-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3-amino-1-pyrrolidinyl)-1-methyl-N-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-62-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[(4-methoxyphenyl)methyl]-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-64-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-methoxyethyl)-1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-63-6
CMF C18 H25 N7 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792967-66-9 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(6-methyl-3,6-diazabicyclo[3.2.2]non-3-yl)-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-65-8
CMF C23 H32 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792967-68-1 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(4-methyl-2-pyridinyl)-N5-(4-piperidinylmethyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 792967-67-0
CMF C21 H30 N8



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 792967-70-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[(2S)-2-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792967-69-2
CMF C20 H28 N8

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 792967-72-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[4-[(methylamino)methyl]-1-piperidinyl]-N-(4-methyl-2-pyridinyl)-3-propyl-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 792967-71-6

CMF C22 H32 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 792967-73-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-74-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N7-(4-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-75-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(1-piperazinyl)-3-propyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-76-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(4-methyl-1-piperazinyl)-3-propyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-77-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[(3S)-3-methyl-1-piperazinyl]-3-propyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-78-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-dimethyl-N5-(1-methyl-4-piperidinyl)-3-propyl-N7-4-pyrimidinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-79-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(6-methoxy-4-pyrimidinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-80-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(6-methoxy-4-pyrimidinyl)-N5,1-dimethyl-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-81-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(6-methoxy-4-pyrimidinyl)-
N5,N5,1-trimethyl-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-82-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(1-piperazinyl)-3-propyl-N-
pyrazinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-83-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(1-piperazinyl)-3-propyl-N-
2-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-84-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(1-piperazinyl)-3-propyl-N-
3-pyridazinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-85-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,N5,1-trimethyl-N7-(5-methyl-1,2,4-oxadiazol-3-yl)-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-86-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-1H-imidazol-2-yl-N5,1-dimethyl-3-propyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-87-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-[(3R)-3-methyl-1-piperazinyl]-3-propyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-88-5 CAPLUS


CN Ethanol, 2-[[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-89-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,1-bis(2-methoxyethyl)-3-methyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-90-9 CAPLUS

CN 4-Piperidinol, 1-[3-ethyl-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-91-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-5-[(3S)-3-methoxy-1-pyrrolidinyl]-3-methyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-92-1 CAPLUS

CN Ethanol, 2-[[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-93-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-94-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-1-(2-methoxyethyl)-N7-(4-methyl-2-pyridinyl)-N5-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-95-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(3-methoxypropyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-96-5 CAPLUS

CN 3-Pyrrolidinol, 1-[1-(3-methoxypropyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-97-6 CAPLUS

CN β -Alanine, N-[1-(2-methoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-98-7 CAPLUS

CN 3-Pyrrolidinol, 1-[1-(2-methoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792967-99-8 CAPLUS


CN 1-Propanol, 3-[[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-00-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(3-methoxypropyl)-3-methyl-N7-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792968-01-5 CAPLUS

CN 4-Piperidinol, 1-[1-(2-methoxyethyl)-3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-02-6 CAPLUS
 CN Piperazinone, 4-[1-(2-methoxyethyl)-3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-03-7 CAPLUS
 CN Propanamide, 3-[[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-N-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792968-04-8 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-05-9 CAPLUS


CN Ethanol, 2-[[3-ethyl-1-(2-methoxyethyl)-7-(2-pyridinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-06-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N7-(5-fluoro-2-pyridinyl)-N5,1-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-07-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-1-(2-methoxyethyl)-N7-(5-


propoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-08-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N7-(5-methyl-2-pyridinyl)-N5-[2-(4-morpholinyl)ethyl]-3-propyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-09-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-methyl-5-(4-methyl-1-piperazinyl)-N-(5-methyl-2-pyridinyl)-3-propyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-10-6 CAPLUS

CN 1-Propanol, 2-[[7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(3-methoxypropyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-11-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-1-(2-methoxyethyl)-N7-(5-methyl-1H-pyrazol-3-yl)-N5-[2-(1H-pyrazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-12-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(3-methoxypropyl)-3-methyl-N-(5-methyl-1H-pyrazol-3-yl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-13-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(2,5-diazabicyclo[2.2.1]hept-2-yl)-1-(3-methoxypropyl)-3-methyl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-14-0 CAPLUS

CN L-Proline, 1-[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-1H-pyrazol-3-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-15-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-methyl-N5-[2-(methylamino)ethyl]-3-propyl-N7-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-16-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(3S)-3-amino-1-pyrrolidinyl]-1-methyl-3-propyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-17-3 CAPLUS

CN 3-Piperidinol, 1-[3-ethyl-1-(2-methoxyethyl)-7-(1H-pyrazol-3-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-18-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(3-methoxypropyl)-3-methyl-N-1H-pyrazol-3-yl-5-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-19-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(5-ethyl-2-pyridinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-20-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-cyclohexyl-1-methyl-5-(1-

piperazinyl)-3-propyl- (9CI) (CA INDEX NAME)



RN 792968-21-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4,6-dimethyl-2-pyridinyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-22-0 CAPLUS


CN Cyclohexanol, 4-[[1-methyl-5-(1-piperazinyl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 792968-23-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4-methoxycyclohexyl)-1-methyl-5-(1-piperazinyl)-3-propyl- (9CI) (CA INDEX NAME)



RN 792968-24-2 CAPLUS


CN 2-Pyridinecarboxamide, N-methyl-6-[[1-methyl-5-(1-piperazinyl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792968-25-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-cyclopentyl-1-methyl-5-(1-piperazinyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 792968-26-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,N7,1-trimethyl-N7-(1-methyl-4-piperidiny1)-3-propyl- (9CI) (CA INDEX NAME)



RN 792968-27-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-28-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-3-propyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-29-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-30-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(5-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-31-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-32-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-33-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(5-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-34-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-35-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-36-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(5-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-37-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-38-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-39-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-(5-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-40-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-methoxyethyl)-3-methyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-41-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-42-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-(5-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-43-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-methyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-44-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-45-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-(5-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-46-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[(2S,5R)-2,5-dimethyl-1-piperazinyl]-1-(2-ethoxyethyl)-3-ethyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-47-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-1-(2-methoxyethyl)-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-48-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-1-(2-methoxyethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-49-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-1-(2-methoxyethyl)-N7-(4-methyl-2-pyridinyl)-N5-[2-(1H-pyrazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-50-4 CAPLUS

CN 1-Propanol, 2-[[3-ethyl-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-51-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-methoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-52-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-53-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,3-dimethyl-N5-[(3R)-1-methyl-3-pyrrolidinyl]-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-54-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(3R)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-55-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(5-methyl-2-pyridinyl)-N5-[(3R)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-56-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-[(3R)-1-methyl-3-pyrrolidinyl]-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-57-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-58-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-59-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2H-pyran-2-yl)methyl]-, dihydrochloride
(9CI) (CA INDEX NAME)




●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-60-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-61-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-62-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-63-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-64-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-65-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-66-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792968-75-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-3-(1-methylethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-, bis(trifluoroacetate) (9CI)

(CA INDEX NAME)

CM 1


CRN 792968-74-2
CMF C21 H30 N8 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 792968-76-4 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-methoxyethyl)-3-(1-methylethyl)-
N-(5-methyl-2-pyridinyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 792968-77-5 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-1-(2-methoxyethyl)-N-(5-
methyl-1H-pyrazol-3-yl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-78-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-79-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 5-(dimethylamino)-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-80-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-N-

(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-81-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-82-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-83-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-methyl-2-pyridinyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-84-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-85-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-N5,N5-dimethyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-86-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N4-pyrimidinyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-87-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-(1-piperazinyl)-N-4-pyrimidinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-88-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,3-dimethyl-N5-[(3S)-1-methyl-3-pyrrolidinyl]-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-89-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N7-(5-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-90-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-ethyl-N5-methyl-N5-[(3S)-1-methyl-3-pyrrolidinyl]-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-91-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-N-(6-methoxy-3-

pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 792968-92-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-N-(5-methoxy-2-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-93-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-N-(6-methoxy-2-pyridinyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-94-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-95-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792968-96-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, N-(5,6-dimethyl-3-pyridinyl)-1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 792968-97-9 CAPLUS

CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 792968-98-0 CAPLUS
 CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-5-[(2-methoxyethyl)methylamino]-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 792968-99-1 CAPLUS
 CN 2(1H)-Pyridinone, 5-[[1-(2-ethoxyethyl)-5-(ethylmethylamino)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-1-methyl- (9CI) (CA INDEX NAME)




RN 792969-01-8 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[3-

(methylamino)-1-azetidinyll]-N-(4-methyl-2-pyridinyl)-, trifluoroacetate
(9CI) (CA INDEX NAME)

CM 1


CRN 792969-00-7
CMF C20 H28 N8 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 792969-03-0 CAPLUS
CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-5-[3-(dimethylamino)-1-azetidinyll]-3-methyl-N-(4-methyl-2-pyridinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 792969-02-9
CMF C21 H30 N8 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 792969-04-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-N-(4-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-05-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-06-3 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-07-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5,3-dimethyl-N7-(6-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-08-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-09-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-10-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-ethyl-3-(methoxymethyl)-N5-methyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-11-0 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-12-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-13-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-[3-(dimethylamino)-1-azetidiny]-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-14-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-[2-(dimethylamino)ethyl]-1-(2-ethoxyethyl)-N5,3-dimethyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-15-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-ethyl-N5,3-dimethyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-16-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-ethyl-N5,3-dimethyl-N7-(2-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-17-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-N5,3-dimethyl-N7-(2-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-18-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-19-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-20-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-[4-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-21-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-22-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-23-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-ethyl-3-(methoxymethyl)-N5-methyl-N7-4-pyrimidinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-24-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 1-(2-ethoxyethyl)-N5-(2-methoxyethyl)-3-(methoxymethyl)-N5-methyl-N7-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-25-6 CAPLUS

CN Ethanol, 2-[[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-


pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl)methylamino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-26-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-methanol, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-27-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-28-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-29-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-3-methyl-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-30-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-31-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(5,6-dimethyl-3-pyridinyl)-1-(2-ethoxyethyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 792969-32-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-N-(4,6-dimethyl-2-pyridinyl)-1-(2-ethoxyethyl)-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-33-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-34-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-35-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(2,5-diazabicyclo[2.2.2]oct-2-yl)-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-36-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-methyl-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-37-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-

methyl-N-(6-methyl-2-pyridinyl)-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-38-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-39-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-40-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792969-41-6P 792969-42-7P, N-[5-[(1R,4R)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-43-8P 792969-44-9P 792969-45-0P, 3-Methyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(6-methylpyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792969-46-1P, N-[3-Ethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyridazin-4-ylamine 792969-47-2P, N-[3-Ethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine 792969-48-3P, N-[3-Ethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-2-methylpyrimidin-4-ylamine 792969-49-4P, 3-Ethyl-N-methyl-N-(1-methylpiperidin-4-yl)-N'-(6-methylpyrimidin-4-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine 792969-50-7P, N-[3-Methoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-51-8P, N-[3-Methoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-53-0P, N-[3-Ethoxymethyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-54-1P, N-[3-Ethoxymethyl-5-((3R)-3-


methylpiperazin-1-yl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-55-2P
 792969-56-3P, N-[3-Methyl-5-piperazin-1-yl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-6-methylpyridin-2-ylamine 792969-57-4P, N-[5-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-3-methoxymethyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792969-58-5P
 792969-59-6P, 1-[3-Methyl-7-(4-methylpyridin-2-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid 792969-60-9P, 1-[3-Methyl-7-(6-methylpyrimidin-4-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid 792969-61-0P,
 1-[3-Ethyl-7-(6-methylpyrimidin-4-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid 792970-85-5P, 3-Methyl-5-((3R)-3-methylpiperazin-1-yl)-1-[2-(n-propoxy)ethyl]-N-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792970-86-6P, 1-(2-Ethoxyethyl)-3-(methoxymethyl)-5-((3R)-3-methylpiperazin-1-yl)-N-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-ylamine 792970-87-7P, N-[5-[(1R,4R)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine 792970-88-8P,
 N-[5-[(1S,4S)-2,5-Diazabicyclo[2.2.1]hept-2-yl]-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE5 inhibitor; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792969-41-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(ethoxymethyl)-N-(4-methyl-2-pyridinyl)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-42-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-43-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,3-dimethyl-N7-(4-methyl-2-pyridinyl)-N5-[(3S)-1-methyl-3-pyrrolidinyl]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-44-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-45-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5,3-dimethyl-N5-(1-methyl-4-piperidinyl)-N7-(6-methyl-4-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-46-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N4-pyridazinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 792969-47-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-4-pyrimidinyl-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-48-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-ethyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(2-methyl-4-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-49-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, 3-ethyl-N5-methyl-N5-(1-methyl-4-piperidinyl)-N7-(6-methyl-4-pyrimidinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-50-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-51-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-53-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-54-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-55-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(ethoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-56-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-N-(6-methyl-2-pyridinyl)-5-(1-piperazinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-57-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-58-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-(methoxymethyl)-N-(4-methyl-2-pyridinyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-59-6 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-60-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(6-methyl-4-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792969-61-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-ethyl-7-[(6-methyl-4-pyrimidinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-85-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-1-(2-propoxyethyl)-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-86-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-(methoxymethyl)-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-87-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-88-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-1-(2-ethoxyethyl)-3-ethyl-N-(4-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792970-50-4P, tert-Butyl 3-[1-(2-ethoxyethyl)-3-methoxymethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate 792970-51-5P, tert-Butyl (1S,4S)-5-[1-(2-ethoxyethyl)-3-methyl-7-(5-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 792970-52-6P, tert-Butyl (1S,4S)-5-[1-(2-ethoxyethyl)-3-methyl-7-[(pyrimidin-4-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 792970-53-7P, tert-Butyl (1S,4S)-5-[1-(2-ethoxyethyl)-3-ethoxymethyl-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 792970-54-8P 792970-84-4P, Ethyl 1-[3-methyl-7-(4-methylpyridin-2-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylate 792970-92-4P 792970-93-5P 792970-94-6P 792970-95-7P 792970-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792970-50-4 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octane-8-carboxylic acid, 3-[1-(2-ethoxyethyl)-3-(methoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-51-5 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[1-(2-ethoxyethyl)-3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-,

Absolute stereochemistry.




CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[1-(2-ethoxyethyl)-3-methyl-7-(4-pyrimidinylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[1-(2-ethoxyethyl)-3-(ethoxymethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-54-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-N-(4-methyl-2-pyridinyl)-5-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-84-4 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-92-4 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-(2-methoxyethyl)-3-(1-methylethyl)-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-93-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-(2-methoxyethyl)-3-(1-methylethyl)-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-94-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3-methyl-7-[(5-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-95-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[3-ethyl-1-(2-methoxyethyl)-7-[(5-methyl-1H-pyrazol-3-yl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-97-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-methyl-7-[(4-methyl-2-pyridinyl)amino]-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted cycloalkyl, cycloalkenyl, (un)substituted pyridin-2-yl, (un)fused Ph, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or NR3R4 = piperazin-1-yl, monocyclic, saturated polycyclic; R5 = (un)substituted halo/alkyl, alkenyl, alkynyl, cycloalkyl; R6 = H, (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, etc.] were prepared as selective PDE5 inhibitors. For example, II•2HCl was prepared from (4-Methylpyridin-2-yl)amine, dichloride III (general preparation given), and tert-Bu piperazine-1-carboxylate. I gave IC50 values < 10,000 nM in an in vitro assay for PDE5 inhibition. Thus, I are used for treating hypertension.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:771374 CAPLUS

DOCUMENT NUMBER: 139:292259

TITLE: Preparation of pyrazolo[4,3-d]pyrimidines as selective inhibitors of cyclin-dependent kinases, cell proliferation inhibitors, and apoptosis inducers for therapy of diseases

INVENTOR(S): Moravcova, Daniela; Havlicek, Libor; Krystof, Vladimir; Lenobel, Rene

PATENT ASSIGNEE(S): Ustav Experimentalni Botaniky Av Cr (Institute of Experimental Botany Academy of Sciences of the Czech Republic), Czech Rep.

SOURCE: Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 1348707 | A1 | 20031001 | EP 2002-7163 | 20020328 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| CA 2480409 | A1 | 20031009 | CA 2003-2480409 | 20030327 |
| WO 2003082872 | A1 | 20031009 | WO 2003-EP3207 | 20030327 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003226731 | A1 | 20031013 | AU 2003-226731 | 20030327 |
| JP 2005527565 | T | 20050915 | JP 2003-580337 | 20030327 |
| US 2005080097 | A1 | 20050414 | US 2004-952087 | 20040928 |
| PRIORITY APPLN. INFO.: | | | EP 2002-7163 | A 20020328 |
| | | | WO 2003-EP3207 | W 20030327 |


OTHER SOURCE(S): MARPAT 139:292259

IT 607729-12-4D, epoxy activated Sepharose 6B-bound

RL: BSU (Biological study, unclassified); BIOL (Biological study) (affinity sorbent; preparation of pyrazolo[d]pyrimidines as selective inhibitors of cyclin-dependent kinases, cell proliferation inhibitors, and apoptosis inducers for therapy of diseases)

RN 607729-12-4 CAPLUS

CN Benzoic acid, 5-[[5-[(2-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)




IT 607725-51-9P 607725-52-0P 607725-53-1P
 607725-54-2P 607725-55-3P 607725-56-4P
 607725-57-5P 607725-58-6P 607725-59-7P
 607725-60-0P 607725-61-1P 607725-62-2P
 607725-63-3P 607725-64-4P 607725-65-5P
 607725-66-6P 607725-67-7P 607725-68-8P
 607725-69-9P 607725-70-2P 607725-71-3P
 607725-72-4P 607725-73-5P 607725-74-6P
 607725-75-7P 607725-76-8P 607725-77-9P
 607725-78-0P 607725-79-1P 607725-80-4P
 607725-81-5P 607725-82-6P 607725-83-7P
 607725-84-8P 607725-85-9P 607725-86-0P
 607725-87-1P 607725-88-2P 607725-89-3P
 607725-90-6P 607725-91-7P 607725-92-8P
 607725-93-9P 607725-94-0P 607725-95-1P
 607725-96-2P 607725-97-3P 607725-98-4P
 607725-99-5P 607726-00-1P 607726-01-2P
 607726-02-3P 607726-03-4P 607726-04-5P
 607726-05-6P 607726-06-7P 607726-07-8P
 607726-08-9P 607726-09-0P 607726-10-3P
 607726-11-4P 607726-12-5P 607726-13-6P
 607726-14-7P 607726-15-8P 607726-16-9P
 607726-17-0P 607726-18-1P 607726-19-2P
 607726-20-5P 607726-21-6P 607726-22-7P
 607726-23-8P 607726-24-9P 607726-25-0P
 607726-26-1P 607726-27-2P 607726-28-3P
 607726-29-4P 607726-30-7P 607726-31-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[d]pyrimidines as selective inhibitors of cyclin-dependent kinases, cell proliferation inhibitors, and apoptosis inducers for therapy of diseases)


RN 607725-51-9 CAPLUS

CN Ethanol, 2-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-52-0 CAPLUS

CN 1-Propanol, 3-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-53-1 CAPLUS

CN Ethanol, 2,2'-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607725-54-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminocyclohexyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607725-55-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(4-aminocyclohexyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607725-56-4 CAPLUS

CN 1-Butanol, 2-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607725-57-5 CAPLUS


CN 1-Butanol, 2-[[7-[(3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607725-58-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607725-59-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminoethyl)-N7-(3-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607725-60-0 CAPLUS

CN Ethanol, 2-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-61-1 CAPLUS

CN 1-Propanol, 3-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-62-2 CAPLUS

CN Ethanol, 2,2'-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI). (CA INDEX NAME)




RN 607725-63-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminocyclohexyl)-3-(1-methylethyl)-N7-phenyl- (9CI) (CA INDEX NAME)



RN 607725-64-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(4-aminocyclohexyl)-3-(1-methylethyl)-N7-phenyl- (9CI) (CA INDEX NAME)



RN 607725-65-5 CAPLUS

CN 1-Butanol, 2-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607725-66-6 CAPLUS


CN 1-Butanol, 3-methyl-2-[[3-(1-methylethyl)-7-(phenylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607725-67-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-3-(1-methylethyl)-N7-phenyl- (9CI) (CA INDEX NAME)




RN 607725-68-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminoethyl)-3-(1-methylethyl)-N7-phenyl- (9CI) (CA INDEX NAME)




RN 607725-69-9 CAPLUS

CN Benzoic acid, 2-chloro-4-[[5-[(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-70-2 CAPLUS

CN Benzoic acid, 2-chloro-4-[[5-[(3-hydroxypropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-71-3 CAPLUS

CN Benzoic acid, 4-[[5-[bis(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 607725-72-4 CAPLUS

CN Benzoic acid, 4-[[5-[(2-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 607725-73-5 CAPLUS


CN Benzoic acid, 4-[[5-[(4-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 607725-74-6 CAPLUS


CN Benzoic acid, 2-chloro-4-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Benzoic acid, 2-chloro-4-[[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




CN Benzoic acid, 4-[[5-[(3-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 607725-77-9 CAPLUS
 CN Benzoic acid, 4-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 607725-78-0 CAPLUS
 CN Benzoic acid, 2-chloro-5-[[5-[(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-79-1 CAPLUS
 CN Benzoic acid, 2-chloro-5-[[5-[(3-hydroxypropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-80-4 CAPLUS

CN Benzoic acid, 5-[[5-[[bis(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 607725-81-5 CAPLUS


CN Benzoic acid, 5-[[5-[(2-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 607725-82-6 CAPLUS

CN Benzoic acid, 5-[[5-[[4-aminocyclohexyl]amino]-3-(1-methylethyl)-1H-


pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)



RN 607725-83-7 CAPLUS

CN Benzoic acid, 2-chloro-5-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-methylethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607725-84-8 CAPLUS


CN Benzoic acid, 2-chloro-5-[[5-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-methylethyl]-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607725-85-9 CAPLUS

CN Benzoic acid, 5-[[5-[(3-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 607725-86-0 CAPLUS

CN Benzoic acid, 5-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-chloro- (9CI) (CA INDEX NAME)




RN 607725-87-1 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[[5-[(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-88-2 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[[5-[(3-hydroxypropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-89-3 CAPLUS

CN Benzoic acid, 5-[[5-[bis(2-hydroxyethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 607725-90-6 CAPLUS

CN Benzoic acid, 5-[[5-[(2-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 607725-91-7 CAPLUS


CN Benzoic acid, 5-[[5-[(4-aminocyclohexyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 607725-92-8 CAPLUS

CN Benzoic acid, 2-hydroxy-5-[[5-[[[(1R)-1-(hydroxymethyl)propyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607725-93-9 CAPLUS


CN Benzoic acid, 2-hydroxy-5-[[5-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607725-94-0 CAPLUS

CN Benzoic acid, 5-[[5-[(3-aminopropyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 607725-95-1 CAPLUS

CN Benzoic acid, 5-[[5-[(2-aminoethyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 607725-96-2 CAPLUS

CN Ethanol, 2-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-97-3 CAPLUS

CN 1-Propanol, 3-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607725-98-4 CAPLUS


CN Ethanol, 2,2'-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)



RN 607725-99-5 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminocyclohexyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-00-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(4-aminocyclohexyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607726-01-2 CAPLUS
 CN 1-Butanol, 2-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-

d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607726-02-3 CAPLUS


CN 1-Butanol, 2-[[7-[(4-bromophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607726-03-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-04-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminoethyl)-N7-(4-bromophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-05-6 CAPLUS

CN Ethanol, 2-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607726-06-7 CAPLUS

CN 1-Propanol, 3-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607726-07-8 CAPLUS

CN Ethanol, 2,2'-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607726-08-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminocyclohexyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607726-09-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(4-aminocyclohexyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-10-3 CAPLUS

CN 1-Butanol, 2-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-

d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607726-11-4 CAPLUS


CN 1-Butanol, 2-[[7-[(4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607726-12-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(3-aminopropyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-13-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N5-(2-aminoethyl)-N7-(4-chlorophenyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-14-7 CAPLUS

CN Ethanol, 2-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607726-15-8 CAPLUS

CN 1-Propanol, 3-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607726-16-9 CAPLUS

CN Ethanol, 2,2'-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607726-17-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(3-amino-4-chlorophenyl)-N5-(2-aminocyclohexyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607726-18-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(3-amino-4-chlorophenyl)-N5-(4-aminocyclohexyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607726-19-2 CAPLUS

CN 1-Butanol, 2-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607726-20-5 CAPLUS


CN 1-Butanol, 2-[[7-[(3-amino-4-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607726-21-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(3-amino-4-chlorophenyl)-N5-(3-aminopropyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-22-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(3-amino-4-chlorophenyl)-N5-(2-aminoethyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-23-8 CAPLUS

CN Ethanol, 2-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607726-24-9 CAPLUS

CN 1-Propanol, 3-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]- (9CI) (CA INDEX NAME)




RN 607726-25-0 CAPLUS

CN Ethanol, 2,2'-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 607726-26-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(4-amino-3-chlorophenyl)-N5-(2-aminocyclohexyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607726-27-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(4-amino-3-chlorophenyl)-N5-(4-aminocyclohexyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 607726-28-3 CAPLUS

CN 1-Butanol, 2-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607726-29-4 CAPLUS


CN 1-Butanol, 2-[[7-[(4-amino-3-chlorophenyl)amino]-3-(1-methylethyl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607726-30-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(4-amino-3-chlorophenyl)-N5-(3-aminopropyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 607726-31-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-5,7-diamine, N7-(4-amino-3-chlorophenyl)-N5-(2-aminoethyl)-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



GI



AB The invention relates to 3,5,7-trisubstituted pyrazolo[4,3-d]pyrimidines represented by the general formula (I) and pharmaceutically acceptable salts thereof [wherein R₃ is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group; R₅ = halogen, NHNH₂, NHOH, NHCONH₂, guanyl (NH-C(:NH)NH₂) an optionally substituted C1-6

alkyl, alkenyl, alkynyl, C3-15 cycloalkyl, Rf(C3-15 cycloalkyl), heterocycle, heteroalkyl, aryl, heteroaryl, arylalkyl, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkyl group, the group CORa, CONRbRc, SO3Rd, or NHC(O)Re [wherein Ra, Rf = optionally substituted C1-6 alkyl, alkenyl, or alkynyl; Rb, Rc, Rd = independently H, optionally substituted C1-6 alkyl, alkenyl, or alkynyl; Re = HO, amino, alkoxy, alkylamino, optionally substituted C1-6 alkyl, alkenyl or alkynyl group, or X-R5' [wherein X = NH, O, S or N(alkyl) and R5' = H, optionally substituted C1-6 alkyl, alkenyl, alkynyl, C3-15 cycloalkyl, Rf(C3-15 cycloalkyl), aryl, heterocycle, hetero C1-6 alkyl, arylalkyl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkyl, the group CORa, CONRbRc, SO3Rd, or NHCORE, wherein Ra, Rb, Rc, Rd, Re and Rf have the above meaning]]; R7 = halogen, NHNH2, NHOH, NHCONH2, guanyl(NH-C(:NH)NH2) or the group X-R7', wherein X has the above meaning of R7' is as defined for R5']. These compds. are useful for treating cancer, or psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft vs. host disease and gout, parasitoses such as those caused by fungi or protists, or Alzheimer's disease, or as antineurogenerative drugs, or to suppress immunostimulation. They are also used for treating an hyperproliferative skin disease in a human suffering therefrom by actinic keratosis, Bowen's disease, papilloma, seborrheic keratosis, toxic eczema, atopic dermatitis and ichthyosis. They modulate the activation of adrenergic and/or purinergic receptors which as a consequence result in the activation or inactivation of adenylate cyclase in cancer, asthma, cardiovascular, neurodegenerative and inflammatory diseases. Also disclosed are (1) a method of eliminating or reducing viral spread or growth in tissue culture systems during the production of biopharmaceutical or other products such as proteins and vaccines, for elimination or reduction of viral spread and growth in clin. samples such as blood, and for stopping of growth of tissue culture cells while leaving the cells to carry on with protein and secondary products (antibiotics, secondary plant products, and the like) production, using the compds. I, (2) a method of suppressing immunostimulation (e.g. arthritis or in suppression of transplant rejection) in mammals by administration of I, (3) a method of inducing apoptosis in mammalian cells by administration of I, (4) a method of inhibiting aging and senescence of mammalian cells, the health and youthful appearance of skin and body using I, and (5) a method of maintaining mammalian oocytes at the germinal vesicle stage and their fertilization during mammalian cloning processes by using I. Disclosed is a method of treating viral infections, in particular those caused by DNA viruses including herpesviruses HSV- 1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7, HHV-8 or vaccinia virus, papilloma viruses, flaviviruses, retroviruses, adenoviruses, cytomegalovirus, and the like.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

| | |
|------------|---------|
| SINCE FILE | TOTAL |
| ENTRY | SESSION |
| 48.84 | 221.15 |

FULL ESTIMATED COST

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE | -7.02 | -7.02 |

STN INTERNATIONAL LOGOFF AT 02:39:32 ON 30 MAR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|--|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | DEC 18 | CA/CAPplus pre-1967 chemical substance index entries enhanced with preparation role |
| NEWS | 4 | DEC 18 | CA/CAPplus patent kind codes updated |
| NEWS | 5 | DEC 18 | MARPAT to CA/CAPplus accession number crossover limit increased to 50,000 |
| NEWS | 6 | DEC 18 | MEDLINE updated in preparation for 2007 reload |
| NEWS | 7 | DEC 27 | CA/CAPplus enhanced with more pre-1907 records |
| NEWS | 8 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS | 9 | JAN 16 | CA/CAPplus Company Name Thesaurus enhanced and reloaded |
| NEWS | 10 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS | 11 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS | 12 | JAN 22 | CA/CAPplus updated with revised CAS roles |
| NEWS | 13 | JAN 22 | CA/CAPplus enhanced with patent applications from India |
| NEWS | 14 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS | 15 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS | 16 | FEB 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS | 17 | FEB 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS | 18 | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS | 19 | FEB 26 | MEDLINE reloaded with enhancements |
| NEWS | 20 | FEB 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS | 21 | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS | 22 | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS | 23 | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS | 24 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS | 25 | MAR 16 | CASREACT coverage extended |
| NEWS | 26 | MAR 20 | MARPAT now updated daily |
| NEWS | 27 | MAR 22 | LWPI reloaded |
| | | | |
| NEWS EXPRESS | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. | | |
| | | | |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability | | |
| NEWS LOGIN | Welcome Banner and News Items | | |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 | | |
| NEWS X25 | X.25 communication option no longer available | | |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:59:08 ON 30 MAR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:59:32 ON 30 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10997191z.str



```

chain nodes :
12 14 15 16 17 18 20
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-12 6-14 7-15 12-17 12-18 15-16 15-20
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
3-9 4-12 7-8 8-9 12-17 12-18 15-16 15-20
exact bonds :
2-7 6-14 7-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

G1:H,Ak

G2:N,Cl,Br,F,I

G3:H,Ak

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS 20:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak



G2 N, Cl, Br, F, I

G3 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10997191y.str



chain nodes. :

12 14 15 16 17 19 20 21 22 23

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

4-12 6-14 7-15 12-16 12-17 15-19 19-20 20-21 21-22 21-23
 ring bonds :
 1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
 exact/norm bonds :
 3-9 4-12 7-8 8-9 12-16 12-17 15-19 19-20 21-22 21-23
 exact bonds :
 2-7 6-14 7-15 20-21
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

G1:H,Ak

G2:N,Cl,Br,F,I

G3:H,Ak



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
 14:CLASS 15:CLASS 16:Atom 17:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS
 23:CLASS

L2 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10997191y.str



chain nodes :
 12 14 15 16 17 19 20 21 22 23
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 4-12 6-14 7-15 12-16 12-17 15-19 19-20 20-21 21-22 21-23
 ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
 exact/norm bonds :
 3-9 4-12 7-8 8-9 12-16 12-17 15-19 19-20 21-22 21-23
 exact bonds :
 2-7 6-14 7-15 20-21
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

G1:H,Ak

G2:N,Cl,Br,F,I

G3:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
 14:CLASS 15:CLASS 16:Atom 17:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS
 23:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS



L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10997191w.str



chain nodes :
12 14 15 16 17 19 22 23
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-12 6-14 7-15 12-16 12-17 15-19 19-22 19-23
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
3-9 4-12 7-8 8-9 12-16 12-17 19-22 19-23
exact bonds :
2-7 6-14 7-15 15-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,Ak

G2:N,Cl,Br,F,I

G3:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
14:CLASS 15:CLASS 16:Atom 17:CLASS 19:CLASS 22:CLASS 23:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS



L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10997191v.str



chain nodes :
 12 14 15 16 17 19 20 21
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 4-12 6-14 7-15 12-16 12-17 15-19 19-20 19-21
 ring bonds :
 1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
 exact/norm bonds :
 3-9 4-12 7-8 8-9 12-16 12-17 19-20 19-21
 exact bonds :
 2-7 6-14 7-15 15-19
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

G1:H,Ak

G2:N,Cl,Br,F,I

G3:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
 14:CLASS 15:CLASS 16:Atom 17:CLASS 19:CLASS 20:CLASS 21:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 and l2 and l4 and l5 sam

SAMPLE SEARCH INITIATED 08:07:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L1 AND L2 AND L4 AND L5

=> s l1 sam

SAMPLE SEARCH INITIATED 08:07:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 4 TO 200

L7 4 SEA SSS SAM L1

=> s l1 or l2 or l4 or l5 sam

SAMPLE SEARCH INITIATED 08:07:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 80 TO 560

PROJECTED ANSWERS: 4 TO 200

L8 4 SEA SSS SAM L1 OR L2 OR L4 OR L5

=> s l2 sam

SAMPLE SEARCH INITIATED 08:07:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L2

=> s l4 sam

SAMPLE SEARCH INITIATED 08:08:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L4

=> s 15 sam

SAMPLE SEARCH INITIATED 08:08:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 560
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L5

=> s 11 or 12 or 14 or 15 full

FULL SEARCH INITIATED 08:08:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 363 TO ITERATE

100.0% PROCESSED 363 ITERATIONS 83 ANSWERS
SEARCH TIME: 00.00.01

L12 83 SEA SSS FUL L1 OR L2 OR L4 OR L5

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 449.00 | 449.21 |

FILE 'CAPLUS' ENTERED AT 08:08:23 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 15
FILE LAST UPDATED: 29 Mar 2007 (20070329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 112

L13 . 6 L12

=> d 113 ibib hitstr abs 1-6

L13 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1202023 CAPLUS

DOCUMENT NUMBER: 145:505469

TITLE: Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide as PDE-5 inhibitors

INVENTOR(S): Entwistle, David Andrew; Marshall, Peter Wallance; Taylor, Stefan Colin John

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 72pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2006120552 | A2 | 20061116 | WO 2006-IB1233 | 20060503 |
| WO 2006120552 | A3 | 20070118 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| JP 2006316058 | A | 20061124 | JP 2006-132110 | 20060511 |
| PRIORITY APPLN. INFO.: | | | US 2005-680445P | P 20050512 |
| | | | US 2005-681711P | P 20050517 |


IT 792970-12-8P 852874-37-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and anhydrous crystalline forms of N-[ethoxyethyl(N-ethyl-N-methylamino)(methylpyridinylamino)pyrazolo[4,3-d]pyrimidinecarbonyl]methanesulfonamide as PDE-5 inhibitors)

RN 792970-12-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-37-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

GI



I

AB The invention comprises anhydrous crystalline forms of

N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide (I), pharmaceutical compns.

comprising at least one such form, methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and methods for preparing such forms. Example compound I was prepared by N-alkylation of di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate with 2-ethoxyethyl bromide; the resulting di-Me 1-(2-ethoxyethyl)-4-nitro-1H-pyrazole-3,5-dicarboxylate, which underwent hydrolysis to give the pyrazole-5-carboxylic acid derivative, which underwent amidation to give the corresponding amide, which underwent reduction to give Me 4-amino-5-carbamoyl-1-(2-ethoxyethyl)-1H-pyrazole-3-carboxylate, which underwent cyclization with N,N'-carbonyldiimidazole to give Me 1-(2-ethoxyethyl)-5,7-dioxo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which which underwent chlorination to give Me 5,7-dichloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate, which underwent substitution with 2-amino-4-methylpyridine; the resulting Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate underwent hydrolysis to give the corresponding carboxylic acid, which underwent amidation to give the methanesulfonamide derivative, which underwent substitution with N-methylethylamine to give compound I. Various methods to obtained different crystalline forms of I is also discussed. Compound I was evaluated for its PDE-5 inhibitory activity.

L13 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:412090 CAPLUS

DOCUMENT NUMBER: 144:450729

TITLE: Preparation of novel 5,7-diaminopyrazolo[4,3-d]pyrimidines as PDE5 inhibitors for treating hypertension

INVENTOR(S): Acker, Brad Alan; Hughes, Robert Owen; Jacobsen, Eric John; Lu, Hwang-Fun; Rogers, Thomas Edward; Tollefson, Michael Brent; Walker, John Keith

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company LLC, USA

SOURCE: PCT Int. Appl., 244 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2006046135 | A2 | 20060504 | WO 2005-IB3326 | 20051017 |
| WO 2006046135 | A3 | 20060817 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |

PRIORITY APPLN. INFO.: US 2004-622941P P 20041028


OTHER SOURCE(S): MARPAT 144:450729

IT 792970-12-8P, Methyl 5-chloro-1-(2-ethoxyethyl)-7-[(4-methylpyridin-2-yl)amino]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(intermediate; preparation of pyrazolopyrimidines as PDE5 inhibitors for treating hypertension)

RN 792970-12-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB Title compds. I [R1 = (un)substituted independently Ph, naphthyl, heteroaryl, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alk(en/yn)yl, cycloalkyl; or NR3R4 = (un)substituted mono- or polycyclyl containing at least one heteroatom; R5 = halo/cyclo/alkyl, alkenyl, alkynyl; R6, which may be attached at N1 or N2 of the pyrazole ring = H, cycloalkyl, alk(en/yn)yl, etc.; and their tautomers, and their pharmaceutically acceptable salts] were prepared as phosphodiesterase 5 (PDE5) inhibitors. Thus, amination of 5,7-dichloro-1-(2-ethoxyethyl)-3-ethyl-1H-pyrazolo[4,3-d]pyrimidine with 2-amino-4-picoline, followed by a second amination of 5-chloro intermediate with 4-piperidinemethanol gave

pyrazolopyrimidine II. In a scintillation proximity PDE5 assay, II inhibited PDE5 with an IC50 value of 0.0728 nM.

L13 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1130641 CAPLUS
DOCUMENT NUMBER: 143:387058
TITLE: Preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V
INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Lu, Hwang-Fun; Marsh, Ian Roger; Morrell, Andrew Ian; Owen, Dafydd Rhys; Palmer, Michael John; Rogers, Thomas Edward; Windslow, Carol Ann
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| WO 2005097799 | A1 | 20051020 | WO 2005-IB891 | 20050330 |
| WO 2005097799 | A8 | 20060216 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2562251 | A1 | 20051020 | CA 2005-2562251 | 20050330 |
| EP 1742950 | A1 | 20070117 | EP 2005-718362 | 20050330 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | |
| PRIORITY APPLN. INFO.: | | | GB 2004-7927 | A 20040407 |
| | | | GB 2004-7946 | A 20040407 |
| | | | US 2004-572024P | P 20040518 |
| | | | US 2004-572049P | P 20040518 |
| | | | WO 2005-IB891 | W 20050330 |

OTHER SOURCE(S): MARPAT 143:387058


IT 792970-12-8P 852874-32-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrazolo[4,3-d]pyrimidines as inhibitors of phosphodiesterase V)

RN 792970-12-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-32-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

GI



I



II

AB Title compds. I [R1 = cycloalkyl, cycloalkenyl, 5-6 membered heteroarom. ring, etc.; R2 = H, alkyl; R3-4 = alk(en/yn)yl, cycloalkyl, etc.; R5 =

amino, alkylenylamino, etc.; R6 = alkyl, haloalkyl, alkenyl, alkynyl, etc.] are prepared For instance II is prepared in 12 steps from di-Me 4-nitro-1H-pyrazole-3,5-dicarboxylate, 2-ethoxyethyl bromide, 2-amino-4-methylpyridine, dimethylaminoacetic acid and dimethylamine. II has an IC50 = 1.12 for phosphodiesterase 5 (PDE5). I are useful for the treatment of diabetes and hypertension.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:472160 CAPLUS

DOCUMENT NUMBER: 143:26628

TITLE: Preparation of pyrazolopyrimidines as cyclic guanylate monophosphate-specific phosphodiesterase type 5 inhibitors

INVENTOR(S): Bell, Andrew; Brown, David; Bull, David; Fox, David; Marsh, Ian; Morrell, Andrew; Palmer, Michael; Winslow, Carol

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 147 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2005049617 | A1 | 20050602 | WO 2004-IB3791 | 20041119 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2545196 | A1 | 20050602 | CA 2004-2545196 | 20041119 |
| EP 1689752 | A1 | 20060816 | EP 2004-798915 | 20041119 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| BR 2004016678 | A | 20070213 | BR 2004-16678 | 20041119 |
| PRIORITY APPLN. INFO.: | | | GB 2003-27323 | A 20031124 |
| | | | WO 2004-IB3791 | W 20041119 |

OTHER SOURCE(S): MARPAT 143:26628


IT 792970-12-8P 792970-37-7P 852874-30-7P
852874-31-8P 852874-32-9P 852874-33-0P
852874-34-1P 852874-35-2P 852874-36-3P
852874-37-4P 852874-38-5P 852874-39-6P
852874-40-9P 852874-41-0P 852874-58-9P
852874-59-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as cyclic guanylate monophosphate-specific phosphodiesterase type 5 inhibitors)

RN 792970-12-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-37-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-30-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-31-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-methyl-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-32-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-33-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-34-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclopentylamino)-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 852874-35-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclohexylamino)-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 852874-36-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-methylpropyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-37-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-38-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-methyl-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-39-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-40-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-

(cyclohexylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 852874-41-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclopentylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 852874-58-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-59-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(pyrazinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
GI



AB The title compds. I [R₁ = (un)substituted cycloalkyl, etc.; R₂ = H, alkyl; R₃, R₄ = (un)substituted alkyl, alkenyl, etc.; R₅ = YCONR₁₅R₁₆; Y = alkylenyl, etc.; R₁₅, R₁₆ = H, (un)substituted alkyl, etc.; R₆, which may be attached at N₁ or N₂, is (un)substituted alkyl, alkenyl, etc.] are prepared. Thus, 1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-5-(pyrrolidin-1-yl)-3-(pyrrolidin-1-carbonyl)-1H-pyrazolo[4,3-d]pyrimidine was prepared from Me 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate and pyrrolidine. Compds. of this invention in vitro showed IC₅₀ values of 0.02 nM to 2.95 nM against cyclic guanylate monophosphate-specific phosphodiesterase type 5.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:472159 CAPLUS

DOCUMENT NUMBER: 143:26627

TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines with phosphodiesterase-5 (PDE5) inhibiting activity

INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Dack, Kevin Neil; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 282 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|--------------|------------------|------------|
| WO 2005049616 | A1 | 20050602 | WO 2004-IB3747 | 20041112 |
| WO 2005049616 | A8 | 20060601 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004290643 | A1 | 20050602 | AU 2004-290643 | 20041112 |
| CA 2546987 | A1 | 20050602 | CA 2004-2546987 | 20041112 |
| EP 1689751 | A1 | 20060816 | EP 2004-798876 | 20041112 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU | | | | |
| CN 1882591 | A | 20061220 | CN 2004-80034570 | 20041112 |
| NL 1027568 | A1 | 20050526 | NL 2004-1027568 | 20041123 |
| NL 1027568 | C2 | 20051130 | | |
| US 2005245544 | A1 | 20051103 | US 2004-997191 | 20041124 |
| NO 2006002950 | A | 20060823 | NO 2006-2950 | 20060623 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | GB 2003-27319 | A 20031124 |
| | | | US 2004-535797P | P 20040112 |
| | | | WO 2004-IB3747 | W 20041112 |
| OTHER SOURCE(S): MARPAT 143:26627 | | | | |
| IT | 792970-12-8P | 792970-37-7P | 792970-70-8P | |
| | 852874-32-9P | 852874-33-0P | 852874-34-1P | |
| | 852874-35-2P | 852874-37-4P | 852874-39-6P | |
| | 852874-40-9P | 852874-41-0P | 852874-58-9P | |
| | 852874-59-0P | 853004-04-3P | 853004-05-4P | |
| | 853004-06-5P | 853004-07-6P | 853004-08-7P | |
| | 853004-09-8P | 853004-10-1P | 853004-11-2P | |
| | 853004-12-3P | 853004-13-4P | 853004-14-5P | |
| | 853004-15-6P | 853004-16-7P | 853004-17-8P | |
| | 853004-18-9P | 853004-19-0P | 853004-20-3P | |
| | 853004-21-4P | 853004-22-5P | 853004-23-6P | |
| | 853004-24-7P | 853004-25-8P | 853004-26-9P | |
| | 853004-27-0P | 853004-28-1P | 853004-29-2P | |
| | 853004-30-5P | 853004-31-6P | 853004-32-7P | |
| | 853004-33-8P | 853004-34-9P | 853004-67-8P | |
| | 853004-68-9P | 853004-69-0P | 853004-70-3P | |
| | 853004-71-4P | 853004-72-5P | 853004-73-6P | |
| | 853004-74-7P | 853004-75-8P | 853004-76-9P | |
| | 853004-77-0P | 853004-78-1P | 853004-79-2P | |
| | 853004-80-5P | 853004-90-7P | 853004-91-8P | |
| | 853004-92-9P | 853004-93-0P | 853004-94-1P | |
| | 853005-33-1P | 853005-34-2P | 853005-35-3P | |
| | 853005-36-4P | 853005-37-5P | 853005-38-6P | |
| | 853005-39-7P | 853005-40-0P | 853005-41-1P | |
| | 853005-42-2P | 853005-43-3P | 853005-44-4P | |
| | 853005-48-8P | 853005-49-9P | 853005-50-2P | |
| RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| (preparation of diaminopyrazolopyrimidines with phosphodiesterase-5 inhibiting activity) | | | | |
| RN | 792970-12-8 | CAPLUS | | |
| CN | 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)- | | | |


7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-37-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-70-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-32-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-33-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-34-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclopentylamino)-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 852874-35-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclohexylamino)-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 852874-37-4 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-39-6 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(5-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 852874-40-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclohexylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 852874-41-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclopentylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 852874-58-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 852874-59-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(pyrazinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-04-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-05-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclobutylamino)-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-06-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclopropylamino)-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-07-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(tetrahydro-2H-pyran-4-yl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-08-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(5-fluoro-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-09-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(6-methoxy-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-10-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-(phenylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-11-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(3-fluorophenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-12-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(2-fluorophenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-13-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(2-fluoro-5-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-14-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(3,4-dimethylphenyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-15-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(3-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-16-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[[(3R)-tetrahydro-3-furanyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853004-17-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-18-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(2-methoxyethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-19-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(3-methoxybutyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-20-3 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-21-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-22-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-23-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-2-yl)methyl]-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-24-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-ethyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-25-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-26-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(6-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-27-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(6-ethyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-28-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4,5-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-29-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(2,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-30-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(3,4-difluorophenyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-31-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(3,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-32-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(2,3-difluorophenyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 853004-33-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(2,5-difluorophenyl)amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 853004-34-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(cyclopropylmethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-67-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-68-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-69-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-70-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-methoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-71-4 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(1-methylethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-72-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[(2R)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-73-6 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-ethyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-74-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclopropylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 853004-75-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-(cyclobutylamino)-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 853004-76-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(3R)-tetrahydro-3-furanyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853004-77-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4,6-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-78-1 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4,5-dimethyl-2-pyridinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-79-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(6-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853004-80-5 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-fluoro-3-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 853004-90-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(2-methoxy-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-91-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(2-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-92-9 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(2,6-dimethyl-4-pyrimidinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-93-0 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853004-94-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-33-1 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[(2S)-2-methoxypropyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-34-2 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-pyridinyl]amino]-1-(2-ethoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-35-3 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-propoxyethyl)-7-(2-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-36-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(cyclobutyloxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-37-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(2,2-difluoroethoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-38-6 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 853005-39-7 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-fluoro-3-methylphenyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 853005-40-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(3,3,3-trifluoropropoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-41-1 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(3-fluoropropoxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI)
 (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-42-2 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[[4-(hydroxymethyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-43-3 CAPLUS
 CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-[2-(cyclobutylloxy)ethyl]-7-[(4-methyl-2-pyridinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-44-4 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 853005-48-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(6-methyl-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 853005-49-9 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(3-methylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 853005-50-2 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)amino]-1-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



GI



AB Title compds. [I; R1 = (substituted) cyclic group; R2 = H, alkyl; R3, R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl; R5 = YCO2R15, YR16; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, etc.; Y = bond, CH2OCH2, alkyne, cycloalkylene; R15 = H, (substituted) alkyl; R16 = tetrazolyl, trifluoromethyltriazolyl, methylsulfonyltriazolyl, etc.; dotted lines = double bonds to form an aromatic ring], were prepared. Thus, title compound (II) (preparation given) inhibited PDE-5 with IC50 = 0.075 nM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:965255 CAPLUS

DOCUMENT NUMBER: 141:410950

TITLE: Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension

INVENTOR(S): Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2004096810 | A1 | 20041111 | WO 2004-IB1433 | 20040422 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004234158 | A1 | 20041111 | AU 2004-234158 | 20040422 |
| CA 2523831 | A1 | 20041111 | CA 2004-2523831 | 20040422 |
| EP 1620437 | A1 | 20060201 | EP 2004-728868 | 20040422 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| BR 2004009903 | A | 20060425 | BR 2004-9903 | 20040422 |
| CN 1780841 | A | 20060531 | CN 2004-80011467 | 20040422 |
| JP 2006524636 | T | 20061102 | JP 2006-500346 | 20040422 |
| NL 1026074 | A1 | 20041101 | NL 2004-1026074 | 20040428 |
| NL 1026074 | C2 | 20050809 | | |
| US 2005043325 | A1 | 20050224 | US 2004-834484 | 20040429 |
| NO 2005004404 | A | 20051124 | NO 2005-4404 | 20050922 |
| PRIORITY APPLN. INFO.: | | | GB 2003-9780 | A 20030429 |
| | | | GB 2003-27748 | A 20031128 |
| | | | US 2003-476678P | P 20030606 |
| | | | US 2004-538147P | P 20040120 |
| | | | WO 2004-IB1433 | A 20040422 |

OTHER SOURCE(S): MARPAT 141:410950

IT 792970-12-8P, Methyl 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate 792970-37-7P, Methyl 5-chloro-7-(4-methylpyridin-2-ylamino)-1-(2-propoxyethyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate 792970-69-5P, Methyl 5-chloro-7-(6-methylpyridin-2-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate 792970-70-8P, Methyl 5-chloro-7-(4-methylpyridin-2-ylamino)-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as

selective PDE5 inhibitors useful in treatment of hypertension)

RN 792970-12-8 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-1-(2-ethoxyethyl)-7-[(4-methyl-2-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-37-7 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-(2-propoxyethyl)-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-69-5 CAPLUS


CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(6-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 792970-70-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidine-3-carboxylic acid, 5-chloro-7-[(4-methyl-2-pyridinyl)amino]-1-[2-(2,2,2-trifluoroethoxy)ethyl]-, methyl ester (9CI)
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted cycloalkyl, cycloalkenyl, (un)substituted pyridin-2-yl, (un)fused Ph, etc.; R2 = H, alkyl; R3, R4 = independently (un)substituted alkyl, alkenyl, cycloalkyl, etc.; or NR3R4 = piperazin-1-yl, monocyclic, saturated polycyclic; R5 = (un)substituted halo/alkyl, alkenyl, alkynyl, cycloalkyl; R6 = H, (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, etc.] were prepared as selective PDE5 inhibitors. For example, II•2HCl was prepared from (4-Methylpyridin-2-yl)amine, dichloride III (general preparation given), and tert-Bu piperazine-1-carboxylate. I gave IC50 values < 10,000 nM in an in vitro assay for PDE5 inhibition. Thus, I are used for treating hypertension.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

32.09

481.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.68

-4.68

STN INTERNATIONAL LOGOFF AT 08:08:52 ON 30 MAR 2007